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Abstract
Multi-View Learning (MVL) is a framework which combines data from heteroge-
neous sources in an efficient manner in which the different views learn from each
other, thereby improving the overall prediction of the task. By not combining the data
from different views together, we preserve the underlying statistical property of each
view thereby learning from data in their original feature space. Additionally, MVL
also mitigates the problem of high dimensionality when data from multiple sources
are integrated. We have exploited this property of MVL to predict chemical-target
and drug-disease associations. Every chemical or drug can be represented in diverse
feature spaces that could be viewed as multiple views. Similarly multi-task learning
(MTL) frameworks enables the joint learning of related tasks that improves the overall
performances of the tasks than learning them individually. This factor allows us to
learn related targets and related diseases together. An empirical study has been carried
out to study the combined effects of multi-view multi-task learning (MVMTL) to pre-
dict chemical-target interactions and drug-disease associations.
The first half of the thesis focuses on two methods that closely resemble MVMTL.
We first explain the weighted Multi-View learning (wMVL) framework that systemat-
ically learns from heterogeneous data sources by weighting the views in terms of their
predictive power. We extend the work to include multi-task learning and formulate the
second method called Multi-Task with weighted Multi-View Learning (MTwMVL).
The performance of these two methods have been evaluated by cheminformatics data
sets.
iii
We change gears for the second part of this thesis towards truth discovery (TD). Truth
discovery closely resembles a multi-view setting but the two strongly differ in certain
aspects. While the underlying assumption in multi-view learning is that the different
views have label consistency, truth finding differs in its setup where the main objective
is to find the true value of an object given that different sources might conflict with
each other and claim different values for that object. The sources could be considered
as views and the primary strategy in truth finding is to estimate the reliability of each
source and its contribution to the truth. There are many methods that address various
challenges and aspects of truth discovery and we have in this thesis looked at TD in a
semi-supervised setting.
As the third contribution to this dissertation, we adopt a semi-supervised truth dis-
covery framework in which we consider the labeled objects and unlabeled objects as
two closely related tasks with one task having strong labels while the other task hav-
ing weak labels. We show that a small set of ground truth helps in achieving better
accuracy than the unsupervised methods.
iv
Acknowledgements
I would like to first and foremost thank Dr. Huan for accepting me in his group and for con-
stantly motivating me throughout my study. His positive words have been a very big source of
inspiration. I would like to thank Dr. Sara Wilson for serving in my committee and I am very
grateful to her for guiding me along the right path when I needed it the most.
I express my gratitude Dr. Jerzy Grzymala-Busse, Dr. Bo Luo and Dr. Zhou Wang for serving
in my PhD committee and giving their valuable suggestions.
I would like to thank my lab mates and my seniors who passed out of the lab for helping me in
various capacities throughout my study.
My sincere gratitude from the bottom of my heart to my parents Mr.K.Chandrasekaran and
Dr.P.V.Geetha without whom this dissertation would not have been possible. Their physical, emo-
tional and financial support is the reason I was able to complete this dissertation.
I would like to thank my husband Mr. Siddharth Gangadhar for being my pillar of support and
for always encouraging me to go after my dreams. This dissertation is a dedication to my three
year old daughter Sahana Goda who has made her share of sacrifices to help me complete my study
here at KU. A special thanks to my parents in-law, Mrs. Radha Gangadhar and Mr. Gangadhar for
their immense support.
Lastly I thank all my close friends and family across the globe who have gone out of their way




1.1 Motivation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.1.1 Cheminformatics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.1.2 Truth Discovery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.2 Contributions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.3 Organization of the Proposal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2 Literature Survey of Machine Learning in Cheminformatics 7
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
2.2 Drug Repurposing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
2.3 Multi-task Learning . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
2.4 Multi-view Learning . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
3 Preliminary Study I: Investigating Multi-view and Multi-task Learning for Predicting
Drug-Disease Associations 16
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
3.2 Related Work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
3.2.1 Multitarget and Multi-task Learning . . . . . . . . . . . . . . . . . . . . . 18
3.2.2 Heterogeneous Data Integration and Multi-view Learning . . . . . . . . . 19
3.2.3 Multi-view Multi-task Learning . . . . . . . . . . . . . . . . . . . . . . . 21
3.3 Learning Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
vi
3.4 Experimental Study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
3.4.1 Data Sets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
3.4.2 Model Construction and Evaluation . . . . . . . . . . . . . . . . . . . . . 26
3.4.3 Performance comparison . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
3.5 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
3.5.1 Statistical Significance . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
3.6 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
4 Weighted Multi-view Learning for Predicting Drug-Disease Associations 36
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
4.2 Related work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
4.2.1 Drug Repurposing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
4.2.2 Data Integration and Multi-view Learning . . . . . . . . . . . . . . . . . . 38
4.2.3 Weighted Multi-view Learning . . . . . . . . . . . . . . . . . . . . . . . . 39
4.3 Methodology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
4.3.1 Notations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
4.3.2 Overview of the Learning Framework . . . . . . . . . . . . . . . . . . . . 40
4.4 Experimental Study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
4.4.1 Data sets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
4.4.1.1 Synthetic Data . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
4.4.1.2 Drug-disease Data . . . . . . . . . . . . . . . . . . . . . . . . . 45
4.4.2 Algorithms/Learning Frameworks . . . . . . . . . . . . . . . . . . . . . . 47
4.4.3 Model Construction and Evaluation . . . . . . . . . . . . . . . . . . . . . 48
4.4.3.1 Model Construction and Selection . . . . . . . . . . . . . . . . 48
4.4.3.2 Model Evaluation . . . . . . . . . . . . . . . . . . . . . . . . . 49
4.5 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
4.5.1 Performance Comparison . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
4.5.1.1 Synthetic Data Set . . . . . . . . . . . . . . . . . . . . . . . . . 49
vii
4.5.1.2 Drug-Disease data set . . . . . . . . . . . . . . . . . . . . . . . 51
4.5.2 Statistical Significance . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
4.6 Conclusion and Future Work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
5 Multi-task with Weighted Multi-view Learning for Predicting Chemical-Target Inter-
actions 57
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
5.2 Related Work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
5.2.1 Data Integration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
5.2.2 Learning Related Targets . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
5.2.3 Multi-task Multi-view Learning . . . . . . . . . . . . . . . . . . . . . . . 60
5.3 Method . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
5.3.1 Notations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
5.3.2 Overview of Learning Framework . . . . . . . . . . . . . . . . . . . . . . 61
5.4 Experimental Study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
5.4.1 Data Sets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
5.4.1.1 Data Preprocessing . . . . . . . . . . . . . . . . . . . . . . . . 65
5.4.2 Feature/View Construction . . . . . . . . . . . . . . . . . . . . . . . . . . 67
5.4.3 Model Construction and Evaluation . . . . . . . . . . . . . . . . . . . . . 68
5.4.4 Performance Comparison . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
5.5 Result Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
5.6 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
6 Literature Survey on Truth discovery 75
6.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
6.2 Facets of Truth Discovery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
6.2.1 Common Strategies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
6.2.2 Input Data and Preprocessing . . . . . . . . . . . . . . . . . . . . . . . . 77
viii
6.2.3 Estimating Source Reliability . . . . . . . . . . . . . . . . . . . . . . . . 78
6.2.4 Assumptions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
6.2.5 Templates of Popular Frameworks . . . . . . . . . . . . . . . . . . . . . . 81
6.2.5.1 Notations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
6.2.5.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
6.3 Applications of Truth Discovery . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
6.4 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
7 A Semi-supervised Approach for Truth Discovery 84
7.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
7.2 Related Work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
7.3 Notations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
7.4 Methodology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
7.4.1 Problem Setting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
7.4.2 Learning with Strong and Weak Truths . . . . . . . . . . . . . . . . . . . 87
7.4.3 Computing Source Weights . . . . . . . . . . . . . . . . . . . . . . . . . 88
7.4.4 Computing Truth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
7.4.5 Updating Truth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
7.4.6 Choice of Source Weight Computation . . . . . . . . . . . . . . . . . . . 91
7.5 Experiments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
7.5.1 Real-world Data Sets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
7.5.1.1 Simulated Data Set . . . . . . . . . . . . . . . . . . . . . . . . 93
7.5.1.2 Weather Data Set . . . . . . . . . . . . . . . . . . . . . . . . . 93
7.5.2 Comparison with Other Methods . . . . . . . . . . . . . . . . . . . . . . . 94
7.5.3 Performance Measure . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
7.5.4 Choosing the Ground Truth . . . . . . . . . . . . . . . . . . . . . . . . . 95
7.6 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
7.7 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
ix
8 Conclusion and Future Work 100
x
List of Figures
3.1 A pictorial represented of curated and inferred associations in CTD . . . . . . . . . 23
3.2 Label correlation of the cardiovascular diseases. AO - Aortic diseases, HF - Heart
Failure, VF - Valve Defects, AR - Arrhythmias, HA - Heart Arrest . . . . . . . . . 25
3.3 Label correlation of the diabetes diseases. AN - Angiopathies, CM - Cardiomy-
opathies, NP - Neuropathies, ME - Mellitus . . . . . . . . . . . . . . . . . . . . . 26
3.4 Comparison of MVL vs CFS for cardiovascular diseases . . . . . . . . . . . . . . 30
3.5 Comparison of MVL vs CFS for diabetes diseases . . . . . . . . . . . . . . . . . . 31
3.6 Comparison of MVL vs learning on individual features for cardiovascular diseases 31
3.7 Comparison of MVL vs learning on individual features for diabetes diseases . . . . 32
4.1 The two views of the synthetic data. The circle and the triangle symbols represent
the two classes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
4.2 CTD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
4.3 A representation of the four views of our drug-disease data set. Each view has N
samples where Xd ji represents sample i from view j. The total number of features
for each data set in the sum of d1,d2,d3 and d4 . . . . . . . . . . . . . . . . . . . 47
4.4 The distribution of the weights across the views controlled by the exponential pa-
rameter p . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
5.1 Label correlation of the three dopamine receptors - DRD1, DRD2 and DRD3 . . . 66
5.2 Label correlation of the three histamine receptors - H1, H2 and H3 . . . . . . . . . 67
xi
5.3 A graphical representation of multiple tasks and multiple views. Each view has N
samples and each view has d1, d2 and d3 number of total features respectively. A
sample from view 1 and task 2 is represented as x12 . . . . . . . . . . . . . . . . . 69
7.1 The figure represents our problem setting where the known ground truths are
shaded in yellow. The rows represent the objects and the columns represent the
properties. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
xii
List of Tables
3.1 Characteristics of the features that form the three views for the data sets . . . . . . 25
3.2 Disease Data Characteristics where the no.of drugs represent the total number of
drugs and the third column represents the active drugs for each disease . . . . . . . 27
3.3 The average F1 score of the five learning methods on the cardiovascular data set . . 28
3.4 The average F1 score of the five learning methods on the diabetes data set . . . . . 29
3.5 Wilcoxon ranked test among the methods for cardiovascular diseases . . . . . . . . 33
3.6 Wilcoxon ranked test among the methods for diabetes diseases . . . . . . . . . . . 33
4.1 Disease Data Characteristics where the no.of drugs represent the total number of
drugs and the third column represents the active drugs for each disease . . . . . . . 48
4.2 The view weights learned by wMVL on the synthetic data set with two views . . . 50
4.3 Comparison of the F1 scores on the Synthetic Set . . . . . . . . . . . . . . . . . . 51
4.4 Performance comparison of the average F1 scores of the five methods on the car-
diovascular data set . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
4.5 Performance comparison of the average F1 scores of the five methods on the dia-
betes data set . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
4.6 Wilcoxon ranked test of wMVL with the other methods for the two disease data sets 54
5.1 The table represents the total number of chemicals for each target and the number
of active and inactive interactions. . . . . . . . . . . . . . . . . . . . . . . . . . . 68
5.2 The number of features of the three views of the two GPCR families . . . . . . . . 68
xiii
5.3 Summary of the model parameters for each learning method . . . . . . . . . . . . 70
5.4 The average F1 score of the five learning methods on the Dopamine data set . . . . 72
5.5 The average F1 score of the five learning methods on the Histamine data set . . . . 73
7.1 Statistics of the three data sets . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
7.2 The performance of the methods with 500 known ground truths . . . . . . . . . . . 96
7.3 Effect of known ground truths on error rates for the weather data set . . . . . . . . 97
7.4 Effect of known ground truths on MNAD values for the weather data set . . . . . . 98
7.5 Effect of known ground truths on error rate and MNAD for Adult and Bank data




We are at a time in history where data is all around us. Every product that is manufactured are
becoming more and more data driven. A lot of this data is open source and available to the public
that makes the inference of data a very hot topic. On one hand, it is a great boon to have abundant
data but on the other hand, it is difficult to obtain labels for all the data that can be used to build
prediction models. Instead of discarding such unlabeled information, there are methods that utilize
them in a way that contributes to the learning process. Similarly, a data point could be expressed in
terms of heterogeneous features that are extracted from different sources. Each source might have
dissimilar statistical property and combining them together would not be a good choice always.
Multi-view learning is a well established concept in machine learning that handles data from
diverse sources as well as utilizes unlabeled samples in learning the prediction function. MVL is
also indirectly combats the issue of high dimensionality when features from varied contributors
are integrated. Although the concept of MVL has been around for quite a few years now, there is




The motivation of the thesis is based on semi-supervised learning that finds its application in many
fields. In our work, we find motivations for it in two directions (i) methodology development (ii)
application. In terms of methodology, we have tried to pick the shortcomings of existing methods
that could be addressed to build better prediction models. In terms of application, there are many
fields that benefit from semi-supervised learning. There are various fields in which obtaining labels
can be very expensive and leveraging these unlabeled data could prove to be beneficial.
1.1.1 Cheminformatics
Cheminformatics is a fast growing branch in the field of chemistry where computational tools and
techniques have been used to draw insights to address traditional problems such as drug discovery.
These in silico methods are used to perform a virtual screening procedure that help in identify-
ing chemicals/compounds of interest. The practice of building prediction models to identify drug
candidates from thousands of chemicals has been adopted for many years. In order to fine tune or
improve the performance of these models, more information regarding the small molecules could
be integrated. Initial methods made use of the fact that compounds with similar structures had
similar activities too. Likewise, this notion was extended to other concepts such as, compounds
with similar side effects could have interactions with similar targets. While this could be extended
to many such similarities, the need to handle such varied feature spaces was needed.
The second aspect of building such activity models is that the cost of getting labeled samples
is both time as well as resource consuming. It is hence desirable to use unlabeled samples too to if
it means better prediction. Our motivation in this application stems from the fact that compounds
can be represented by very high dimensional feature spaces accrued from multiple sources. MVL
helps in mitigating the ill effects of both the aforementioned problems.
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The third aspect in cheminformatics that drew our attention is the availability of a huge number
of related tasks. Multi-task learning is another concept in machine learning which states that, learn-
ing multiple related tasks together is beneficial than learning each task separately. The assumption
here is that the tasks are related. Learning dissimilar tasks can lead to performance degeneration.
The second advantage of MTL is that, a single task with low sample size when put together with
a related task leverages its data. Hence MTL is also used to address low sample size. This closely
related to the fact that two targets from the same family of proteins have high chances of being sim-
ilar. For example dopamines D2 and D3 belong to a subclass of a family of proteins called GPCR
and are bound to have very similar functional properties and so learning them together would be
the right choice to make.
We also study drug-disease associations where drugs could be expressed in terms of their struc-
ture, activity with genes, pathways, side effects, etc,. which can be viewed as a multi-view prob-
lem. These genes in turn could be associated with a disease thereby letting us form an inferred
relationship between a drug and a disease. Similar to the previous example, related diseases can be
modelled together as a multi-task problem. In all of these applciations, each view do not have the
same potential to predict a given task. These examples in cheminformatics pushed us to postulate
two methods called the weighted Multi-view Learning and Multi-task with weighted Multi-view
Learning.
1.1.2 Truth Discovery
Due to the information burst in current times and the availability of information regarding an object
across platforms, it is a challenge to discover the truth of an object from a list of so called facts
that are available across numerous sources. An example of such a scenario would be the location
of a person so that customized ads could be recommended. The location could be collected from
Facebook, Twitter, LinkedIn, Instagram, personal webpage and so on. Sometimes an unused plat-
form by the user could carry outdated information while some other sources could copy this false
3
information. The challenge is to account for all these limitations while trying to find the truth about
that object.
This aspect of multiple sources was our primary motivation to cast this as a multi-view prob-
lem. Current methods are scarce when it comes to addressing truth discovery as a learning problem.
Since the truths are not just binary, we also explore the combination of multi-view in a multi-class
setup. Currently, there is a huge gap in this area and so we have tried to introduce the concept
of semi-supervised learning that could potentially open up many avenues in this direction. A key
difference between MVL in a traditional setup and truth dsicovery is that, a fact represented by
two or more views might be in conflict with each other.
There are many more shortcomings in the current methods and many applications that need
to be enriched with better techniques and this thesis contributes in a small way among the many
possibilities.
1.2 Contributions
The contributions of this thesis can again be divided into two categories namely (i) application
and (ii) methodology. In terms of application, we have tried to introduce advanced machine learn-
ing algorithm such as multi-view and multi-task learning frameworks to predict interactions such
as chemical-target and associations like drug-disease relationships. On one hand, the computer
science community is churning out sophisticated prediction frameworks and on the other hand,
researchers of the bioinformatics and cheminformatics communities still resolve to ML algorithms
such as support vector machines, k-nearest neighbors, decision trees and neural networks for pre-
diction purposes. The bridge this gap, we performed empirical studies of using multi-view and
multi-task algorithms in cheminformatics.
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In terms of methodology we have come up with two frameworks that are based on multi-view
learning. The traditional multi-view learning assumes that each view has equal predictive power.
Our hypothesis is that, some views might be better than others in terms of their predictive capa-
bility. The weighted Multi-View Learning (wMVL) addresses this by automatically learning the
weights of the views without any prioir information. MVL learns a function using both labeled and
unlabeled samples and the weights are estimated using the labeled samples. We then extend the
wMVL framework to combine multi-task learning with the weighted multi-view framework. It has
already been shown in the literature that multi-view multi-task learning that combines the advan-
tages of learning from multiple sources and multiple related task is a better framework than each
of them separately. This idea led us to extend the wMVL framework to include multi-task learning
thereby proposing the Multi-Task with weighted Multi-View Learning framework (MTwMVL).
Both these methods were evaluated by using drug-disease and chemical-protein datasets respec-
tively.
The third method that we proposed focuses on the concept of truth discovery that has simi-
larities with multi-view learning. In a multi-view setting, each sample is represented in terms of
different set of features in each view whereas in truth discovery, the same set of objects and their
facts are collected from multiple sources that might conflict with each other. The end goal of truth
discovery is to find the truth of each object from the given set of conflicting facts. One of the
main assumptions of MVL is label consistency where the label of a sample is the same across all
the views. Truth discovery differs in the fact that facts of an object from two sources might not
agree with each other. In order to present a new perspective to truth discovery, we project it as
a semi-supervised learning method and borrow some concepts from MTL. The method has been
evaluated using real world data sets.
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1.3 Organization of the Proposal
The thesis first covers a literature survey of cheminformatics including topics such as drug-target
interaction, drug-disease associations and the concept of drug repurposing. The chapter also in-
cludes discussions on the machine language algorithms widely used for predicting such interac-
tions and associations following which we concentrate specifically on multi-view and multi-task
learning frameworks. The third chapter explores the empirical of multi-view multi-task learning
for predicting drug-disease associations and the fourth chapter presents the systematic study of
multi-task learning for chemical-protein interaction. In the fifth chapter, we have come up with
a weighted multi-view learning framework that estimates the weights of the views thereby pre-
senting the idea that some views might have a better prediction power than the others. The sixth
chapter then extends the weighted multi-view framework to integrate multi-task learning. Both
these methods are evaluated using datasets from cheminformatics. The focus of this thesis then
changes to truth discovery which is similar to multi-view learning where the goal is to find the
truth of an object from multiple sources give that the information amongst them has a conflict. We
finally present a semi-supervised learning framework for truth discovery. We conclude the thesis
by proposing future directions for the semi-supervised truth discovery framework as well as truth




Literature Survey of Machine Learning in
Cheminformatics
2.1 Introduction
Cheminformatics has been looked at as a tool used to fasten the process of drug discovery at var-
ious stages along the entire process. The strength and the huge development in cheminformatics
lies in the ability to have access to a huge wealth of data in the public domain that has over the
years increased exponentially. With huge sets of data deposited in databases with open access, the
potential of exploiting them increased drastically. The ultimate goal of drug discovery is to zero-
in on a chemical/compound that had the capability to interact with a target such as a protein to
modulate it to produce the desired effect. Discovering such new associations has been the central
theme in drug development. This process involves screening several thousands of small molecules
or chemicals as a first stage to short-list candidates that make it to the clinical trials. Since physi-
cal testing of every chemical is a long and a time consuming process, researchers resolved to use
computational tools to help them speed up this stage of screening the molecules. Virtual screening
(VS) as it was called involved searching the library of chemicals to identify the ones to most likely
to bind to a target. VS could be broadly classified into two categories namely: ligand based and
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structure based methods.
Initial literature points to the development and establishment of Quantitative Structure Active
Relationship (QSAR) models which predicted the activity of small molecules with targets based
on their structure. The idea behind these models was that molecules with similar structure had
similar activity profiles. One of the popular ways of establishing QSAR was by using machine
learning techniques like Support Vector Machine (SVM), Neural Networks and Decision Trees. A
key factor that has helped the growth of building prediction models can be attributed to the public
databases (that are open source) that has a wealth of information in the form of bioassays, cura-
tion of the literature, toxicology studies and manually curated relationships. Some of the popular
databases are PubChem [72], KEGG [69], Comparative Toxicogenomic Database [30], ChEMBL
[51], DrugBank [79] and SIDER [76]. These databases contain chemical-target, chemical-pathway,
chemical-gene, annotated drug side effects and other inferred relationships.
Machine learning algorithms were used for building QSAR prediction models both in a super-
vized as well as unsupervised learning approaches [122][15]. Preliminary empirical studies uti-
lized SVM to build classification models to predict chemical-protein interactions [127][16][17][7].
A key feature in such predictions is the features/descriptors used in characterizing the small molecules.
Over the years, researchers have exploited different aspects of drugs to discover these associations.
While structural properties were the beginning point, many other characteristics of the compounds
such as their genomic similarity, side effect similarity and pharmacological profiles were also uti-
lized [127][17]. These spaces in addition to being used individually were also combined together
to achieve better prediction results. Due to wide range of descriptors available to model drugs,
empirical studies have been carried out to study their importance and significance. Alexious et
al., [74] studied in detail the molecular descriptor space. Although their aim was to benchmark
the descriptors, it showed that the different characteristics of a drug represented a whole different
perspective and that the descriptors were not redundant. Example of such features are the 2D struc-
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tural properties, extended circular fingerprints and pharmocophore descriptors. Beyond the initial
application of existing algorithms, they were further fine tuned to highlight the importance of pa-
rameter selection and variable selection for QSAR models using SVM [98][131]. Self organizing
maps were successfully used to differentiate substrates from inhibitors of P-glucoprotein. Given
that both the substrate and inhibitor have the same interaction with the inhibition site, the success-
ful differentiation using SOM was a right step in the direction of using ML for virtual screening
[122].
A recent article by Lavecchia discusses the impact of ML approaches in drug discovery [78].
It details the scope and limitations of SVM, Decision Trees, kNN, Neural networks, Naive Bayes
and SOM in ligand based virtual screening. Algorithms were not used just to build classifica-
tion models but were also used for regression [110]. Partial least squares and boosted support
vector regression methods have been used to establish QSAR [28][147]. Cross validation and
bootstrapping methods were explored to build robust models that achieved better generalization
performance. The major setback or hurdle in cheminformatics that might deteriorate the perfor-
mance of prediction is the high dimensionality. As more spaces are explored, the dimensions can
increase drastically. In order to combat this drawback, feature selection methods were adopted.
An example of one such work is the stepwise exploration of the features using genetic algorithms
and the concept of entropy [43].
Advanced ML frameworks such as active learning and ranking were used to find potential can-
didates [123][2]. Warmuth et al., showed that the active learning paradigm in machine learning
clearly outperformed simpler techniques to choose the active compounds iteratively in each stage
of the drug discovery process. Their work combined active learning with SVMs in selecting the
active compounds in fewer iterations compared to other linear selection models. A similar work
used active learning with SVM to classify cancer genes [89]. The comparison of active and passive
learning showed significant difference in the performance of the classifiers which is advantageous
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since active learning requires very small set of labeled samples. Experiments on gene classifica-
tion of lung, colon and prostate cancer show that the labeled samples needed was contrastingly
lesser for active learning - 31 samples vs 174 samples. Another aspect of drug discovery is to rank
the chemicals to prioritize them instead of using them to build classification or regression models.
Agarwal et al., [2] adopted ranking methods used in web retreival applications to perform empir-
ical studies in virtual screening and have shown that the ranking algorithms identified potential
candidates better than classification and regression models. A key feature of CPI interactions is
that the ratio of the number of positive interaction samples to the number of negative samples is
very low.
The challenge of predicting CPI associations using such imbalanced data has been combated
by adopting data level as well as algorithmic level strategies [42]. Eitrich et al., addressed the
problem of imbalanced data at the data level by sampling the data (either over sampling of the
minor class or down sampling of the major class) and moving the threshold value in tandem with
feature selection. A similar approach was used to screen drugs in PubChem by Li et al., [83]
where they adopted a down sampling method since the ratio of the actives to inactives was as low
as 1:377. But most of these works here experimented with SVM as the base classifiers which still
leaves a huge gap between the advanced machine learning tools and the lack of their applciation
in cheminformatics. Varnek et al., [114] have done an exhaustive work on the methods and trends
of machine learning techniques in cheminformatics. They attribute the challenges in this field to
incompleteness of molecular descriptors, accounting for multiple species and in-silico design of
new molecules. They highlight the drawbacks of ML techniques not performing well on an external
dataset since the training and test data might belong to different data domains. The paper explains
in detail the statistical inference and modeling level view points of machine learning algorithms that
are promising, their achievements in cheminformatics and other approaches that could be useful
in improving the prediction accuracy. Yamanishi et al., [129] used multiple regression kernels for
predicting drug-side effects relationship using a combined feature space of chemical and biological
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spaces. With data science moving in the direction of large-scale analysis, the cheminformatics
community is not far behind. Virtual screening has also delved into scalable algorithms that can
handle huge amounts of data [124][108][6][64]. Prometheus - a software environment to screen
millions of compounds to identify novel drug leads was used to prioritize compounds for biological
screening. The authors [124] used Prometheus to dock about a million compounds into the estrogen
receptor.
2.2 Drug Repurposing
Due to the long process and resources involved in discovering chemical-target interactions, another
novel idea called drug repurposing made inroads in drug discovery [99][100][31]. The drugs go
from screening to clinical trials to approval. The idea was to use already approved drugs and find
newer targets for them. Initial drug discovery was based on the fact that compounds that had sim-
ilar structures had similar interactions. This resulted in finding multiple compounds for a target.
Drug repruposing on the other hand tried to find multiple targets for a single approved drug. This
was beneficial since the intial stages of screening could be bypassed. Drug repositioning can be
roughly categorized into categories namely drug based and disease based [41][106]. While the
former methods initiate discovering associations from a chemical perspective, the latter is initial-
ized from a pathological point of view or from a clinical perspective. Drug based studies focus
on targets having similar binding sites by evaluating chemical-target interactions. Drug-disease
based drug repurposing approaches aim at finding chemicals to new indications for which it was
not originally approved for [62]. A few of the databases that help in both these types of approaches
are MEDLINE [49], SIDER [76] and CTD [30] where a variety of data such as genomic and high
throughput screening results are recorded. A rich set of information is also manually curated from
the literature to establish inferred relationships [4][31].
PREDICT, a large scale prediction method of drug indications was proposed by utilizing drug-
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drug and disease-disease similarities for prediction. The main contribution by the authors showed
that by using disease specific genetic signatures, the accuracy of predicting drug indications for
new diseases could be improved. This would mean that, drug treatments could be personalized for
patients based on their genetic makeup instead of a generic disease signature. Cheng et al., devel-
oped three types of inference methods based on network theory to predict drug-target interactions
for drug repurposing [24]. While the first two methods were drug-based and target-based similarity
inferences, the third method was network-based inference. Each drug and target were represented
as the nodes of a bi-partite graph and the nodes were connected based on the presence of an in-
teraction between the drug and target. By propagating the scores in the network, new associations
were discovered based on the score of the edges previously not defined. They showed that the
network-based inference performed much better than the other two methods. The winning method
was further enhanced by defining the edges as a weighted connection instead of an unweighted
graph [22]. In all of these works, there has been a constant push to integrate various chemical and
disease spaces to build better prediction models [100][25].
2.3 Multi-task Learning
Multi-Task Learning is a powerful concept in machine learning which states that learning mul-
tiple related tasks together is better than learning each individual task separately. This concept
of learning related tasks drew inspiration from real life examples were learning similar tasks like
riding a bicycle and a bike together is efficient than learning each of them separately. MTL has
for this reason been used in a wide range of applications such as [115][19][46]. Over the years,
MTL framework has evolved in various aspects to accommodate different improvisations to make
the general framework better. Some examples are feature selection for similar tasks [5], automatic
inference of task relationships [112][45] and structured input structured output [48]. With its wide
reach to a lot of applications, MTL also found a strong foot in cheminformatics. In the paper titled
"Machine Learning Methods for Property Prediction in Cheminformatics", the authors have sum-
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marized ML techniques that have shown promise in cheminformatics for building structure-activity
models, structure-property models and accounting for multiple molecular species among the many
other uses [114]. The authors have elucidated the advantages of MTL over single task models in
cases where obtaining positive labels is expensive and how a small set of labeled samples across
multiple related tasks can help each other when learnt jointly. To further substantiate on this point,
Geppert et al., showed that MTL was helpful in what is called "Orphan" screening in which some
molecules do not have any ligand information [52].
Ning et al.,proposed an MTL framework for virtual screening using back-propagation neural
networks [97]. The framework was developed to study structure-selectivity relationship (SSR) and
the performance of their SSR-mt method performed substantially better than other baseline SSR
models. Hughes et al., worked on a Deep Learning MTL network to accurately detect the binding
sites and the probability of reactivity for small molecules with glutathione, cyanide, protein and
DNA [61]. Apart from multi-task learning, MTL matrix completion was unearthed by Kshirsagar
et al., for jointly learning protein interactions across related diseases namely Hepatitis C, Ebola
and Influenza A [75]. The model learns a common low-dimensional subspace for task sharing
in addition to task specific sturucture. In addition to the few studies listed above, MTL has been
applied to improve prediction of cancer drug sensitivity and predict genetic traits [58][135]. The
application of MTL specific to chemical-protein interaction has been explained in Chapter 3.
2.4 Multi-view Learning
A lot of applications that build predictive models have samples/observations that can be defined
by more than one feature space. Each feature space is characterized by its statistical properties
which might differ from other feature spaces. For example, in image classification, there might be
a caption under the image that gives a short description and a main text that explains the image.
Each of these text represent a different feature space. Combining the two feature spaces together
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to build a model might not be effective in all cases since it might distort the characteristics of the
feature spaces. Instead multi-view learning (MVL) treats each of these feature spaces as views and
formulates the views to teach other than combining them into a single view. The basic assump-
tions of multi-view learning are as follows: (i) the views are conditionally independent (ii) each
view is sufficient to build a predictive model and (iii) The views agree on the labels. MVL is a
semi-supervised model where there there is a small set of labeled samples and a set of unlabeled
samples for each view. The model learns a function for each view on the labeled samples and the
view iteratively teach each other the labels on the unlabeled samples. The two popular strategies
for MVL are (i) Co-training and (ii) Co-regularization.
In applications such as predicting drug-target interactions, protein-protein interactions and
other such association predictions, it is common to represent a sample by multiple feature spaces
such as chemical, biological and genomic spaces. A common strategy to learn from heterogeneous
spaces was to combine them into a single feature space. This strategy has two main disadvantages.
The first drawback is that, the statistical property of the spaces might not be preserved. The sec-
ond disadvantage is that by combining more spaces for relatively the same number of samples, the
dimension of the data might increase drastically. High dimensionality is a well known problem in
the area of machine learning. Hence MVL combats both these drawbacks effectively and improves
the performance of the predictive model. Although such strategies are relatively new to the chem-
informatics community, Kang et al., used MVL for virtual screening [70]. The different views
were integrated using rank aggregation and the experimental results showed that it is desirable to
combine the views than learn a model on each feature space separately. A more detailed work on
MVL has been explained in Chapter 3.
Another branch that stems from both multi-target and multi-view learning is multi-task multi-
view learning that combines the properties of both the frameworks that learns related multiple
tasks, each of which draws its data from different feature spaces. MVL and MTL have had very
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limited studies in cheminformatics and our preliminary study of applying MTMVL to predict drug-
disease association shows the promise of such frameworks. This dissertation aims at improvising
the MTMVL framework by weighting the views based on its predictive power. We have come up
with the weighted framework for two categories of problems. The first category of problems are
those that need to build predictive models in a multi-view setting where the views agree with each
other and the tasks are related to each other. The second category of problems is the application
of weighted multi-view multi-task framework for truth discovery in a semi-supervised setting.
Here the views might contradict each other and the challenge is to learn the view weights under
the disagreement constraint. We also extend it as a multi-task problem where one task has known
ground truth and the other task learns from weak truths. The details of the framework are discussed
in detail in Chapter 8.
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Chapter 3
Preliminary Study I: Investigating
Multi-view and Multi-task Learning for
Predicting Drug-Disease Associations
3.1 Introduction
Drugs exhibit their therapeutic effects by interacting and modulating one or multiple protein tar-
gets simultaneously; hence deeper insights of complex drug-disease-targets associations is of
paramount importance in drug discovery. During the last decades the idea of drug re-purposing
has been explored, where an old drug is utilized to treat a new disease. Unveiling potentially new
and interesting drug-disease-target associations is a challenging task, considering the complexity
of biological systems. Hence novel computational approaches are of high demand to analyze,
disseminate and predict new interesting interactions, utilizing the growing body of data from dif-
ferent domains, which could then act as starting point for therapy development. Recently, the idea
of data integration has been gaining momentum, where information from heterogeneous sources
is combined with the expectation to provide additional information regarding the underlying links
between drugs-diseases-targets, that otherwise would be difficult to study. In this study, we investi-
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gate a new direction for studying drug-disease associations by utilizing and combining multi-view
and mutli-task learning through integration of heterogeneous source of data. Our results show
the advantages of exploring these methods to more effectively combine information from varied
sources. We use multiple data sets to show the consistency of the results obtained.
3.2 Related Work
Drug discovery is a time and resource intensive process, hence novel approaches are required to
study drug-protein interactions in a more efficient manner [86][40]. Drug-target deconvolution is
a crucial step in drug discovery process since it provides valuable insights of drugs mode of action
and leads to development of safer and improved therapeutic agents. Computational approaches
can provide valuable inputs during decision making stages complementary to well established but
expensive in-vitro and in-vivo methods for identifying and prioritizing promising candidates for
further investigation. During the last decade availability of data regarding diseases, disease associ-
ated genes, biological pathways and drugs side-effects has been growing at an exponential rate in
public repositories such as BindingDB [87], REACTOME [67] and KEGG[68]. Due to the long
timeline and high costs involved in drug discovery, researchers turned to computational tools to
speed up the process in the pipeline. Although computational tools are not meant to completely
replace physical testing in drug discovery, they greatly help in reducing the time taken to zero in
on the potential candidates by shortlisting them from a large pool of drugs. With an increase in
the volume of such interaction information, new horizons opened up in research for the use of
computational tools that helped in drawing conclusions regarding the interaction associations [26].
In addition to finding new drugs, there has been a lot of advancements in using indications of
existing drugs for a newer disease for which it was not originally approved for [13][4][99][130].
Drug repurposing has been looked at from different angles in terms of how to amalgamate available
data to find new associations or how to predict adverse effects of novel drugs [31]. Most of the
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computer aided methods that were used for drug reuse were based on graph network analysis. A
majority of the methods involved the construction of a network of known drugs, diseases, genes
and targets whose interactions and associations were quantified using a scoring function [24][29].
Other than network analysis, machine learning techniques have also been used to build models for
predicting drug-target interactions and for drug repurposing. For example, Yang et al. used the
probability matrix factorization (PMF) method for drug repurposing that combined heterogeneous
data to form a drug-disease association. The chain was defined by multiple factors namely, drug-
target-pathway-gene-disease associations and a multi-level scoring system was used to predict the
drug as being therapeutic, marker/ mechanism or both. A similar work of using PMF was studied
by Cobanoglu et al. for predicting drug-target interactions with the assumption that a low rank
subspace could capture large interaction networks [27].
3.2.1 Multitarget and Multi-task Learning
Drug repurposing is based very closely on the fact that a single chemical can have multiple targets.
Promiscuity of drugs that was initially considered harmful was then exploited to model the multi-
target property of drugs. Combination drugs also impacted multiple targets simultaneously and so
algorithms that could predict and tap into this information gained popularity. One of the ways to
tackle the multitarget scenario has been to utilize multi-label learning where the output learned is
a binary vector. Afzal et al., [1] used a multi-class multi-label approach to model the target-ligand
interactions in ChEMBL where each instance could have more than one label associated with it.
They adopted a Naive Bayes framework in which a binary classifier was constructed for each (l,¬l).
Similarly Cheng et al., followed a multi-label approach to model chemical-protein interactions by
constructing binary classifiers on each label [24] . Multi-task Learning (MTL) has also been used
in cheminformatics in terms of the multi-target (mt) problem where a drug has an interaction with
multiple targets [44][148].
We can roughly divide the MTL work in cheminformatics into the following two broad cat-
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egories namely (i) use of kernel methods and (ii) other methods with the former dealing more
with the use of kernel functions and the latter encompassing a wide variety of MTL methods. We
summarize a few methods here although the literature is not limited to these approaches. Ning
et al., [96] proposed a method to capture the dependencies of related targets and ligands through
target/compound specific kernels that were used simultaneously during the SVM learning process.
Bickel et al., [11] was used for HIV therapy screening by using a drug feature kernel and virus
mutation kernel as prior information in estimating the joint distribution of the data for each task.
The prior information is based on the assumption that different drug combinations can have similar
activity. ProdiGe is one of the popular methods for prioritizing disease genes [93] where heteroge-
neous information like phenotype similarity is shared across diseases in a positive and unlabeled
learning setting. The amount of information that is shared is controlled by a kernel function using
multi-task learning as the backbone.
Cheng et al., modelled the property of a drug’s interaction with multiple targets as a multi-
label problem by using a one-versus-the-rest classifying approach. This however did not ex-
ploit the actual multi-task learning capability. Similar to HIV, Alzheimer’s is another disease
that has been gaining popularity in terms of using multi-target techniques in finding potential tar-
gets [14][47][33]. Fang et al., also defined the mt chemical-protein interaction of ligands against
Alzheimer’s as a multi-label problem. Zhang et al., [139] used task regularized and boosted MTL
for protein-chemical interaction prediction. In this paper, we use a regularized MTL framework
for predicting drug-disease association.
3.2.2 Heterogeneous Data Integration and Multi-view Learning
The most crucial and important part of studying interactions of biomolecules for drug repurposing
or to discover new associations is the quality of data at hand. With abundant data in the public do-
main, there has been a need to extract less noisy data and also to integrate the data from different
sources. On one hand we have databases that are very specific to one kind of data and on the other
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hand have databases that have a wealth of information that encompass a wide range of data char-
acteristics. For example, SIDER [76]is a database that exclusively lists drugs and its side effects
whereas CTD includes data regarding pathways, genes, drugs and their associations. One of the
challenges in drug discovery that has been gaining importance in the past decade is to combat the
problem of combining all these data in a way that is useful for gaining insights [142][109][128].
There has been a growing body of work where researchers found the usefulness of accommodating
diverse data [101][63] and its potential to reveal exciting, new observations. Waller et al, [117]
studied the techniques available at a systems level in terms of how large scale data are integrated,
stored and retrieved and the cost associated with managing such a system. We try to focus on a
different aspect of how to learn from this wealth of information to unearth unknown relationships.
Keeping this in mind, we focus on Multi-view Learning that addresses the issue of learning
from multiple sources. Multi-view learning (MVL) takes into account the heterogeneous sources
from which data is extracted and considers each source as a view. The basic assumption in MVL
is that each view is adequate for building a predictive model and that is conditionally independent.
The advantage of using MVL is that each feature space might have an underlying statistical prop-
erty and concatenating them together might not be meaningful always. Yu et al., [134] proposed
a multi-view setting for mining biomedical text records for gene prioritization. Different vocabu-
laries are each considered as a view and the authors intended to show the promise of using MVL
in a scenario when we do not for sure know which vocabulary is the best to use. They show that
MVL is better than each single view learning. Virtual screening can involve multiple factors like
ligand or target based screening or use interaction data. Kang et al., [70] showed that MVL can
enhance the learning performance by the views teaching each other rather than learning form a
single view. Similar studies were performed for gene clustering from microarray data [111] and
for ligand based screening for drug discovery [143]. The latter paper discusses about how each
platform can have different measurements and how MVL can exploit these heterogeneous data
sources.
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3.2.3 Multi-view Multi-task Learning
The third algorithm - multi-view multi-task learning (MVMTL) combines the advantage of both
MVL and MTL by learning multiple views across multiple tasks. The driving motivation behind
this learning is the fact that many real world data sets might involve multiple views as well as
multiple tasks from which it can learn. For example, proteins can have features from multiple
views such as their 3D structure and their sequence. They can also be characterized by their ac-
tivity with protein families other than it’s own and also by their functional activities. By learning
from a diverse set of features, it is possible to unearth some unknown properties or activities of the
proteins. Likewise, similar proteins when learned together act as extra information for each other
which makes these type of algorithms very relevant for applications that can exploit information
from varied sources to the maximum benefit of the task being learned. A graph based framework
was proposed for MVMTL by [59] where each task could have their own specific view as well
as shared view across different tasks. So for the example explained above, some proteins might
have additional data from a source that other proteins might not have. This data could therefore
be viewed as a task specific view whereas features such as the protein sequence could be a shared
view assuming that the sequence for the proteins are known. Another framework for MVMTL was
proposed by Zhang et al., [138] which differed from He’s method in the fundamental basis that the
former is a transductive learning method and the latter has an inductive learning setup. Zhang fur-
ther showed the promise of this framework by utilizing it to predict adverse drug reactions [137].
Another significant work in this direction is by Jin et al., [66] who went a step further to propose
a setting where tasks with multiple views and other related tasks need not have the same type of
labels. In this study we have utilized the framework proposed by Zhang et al., due to its appropri-
ateness to our application.
In this empirical study, we aim at building statistical models that are capable of predicting drug-
disease associations and in particular cardiovascular and diabetes diseases. Our main motivation
to work on these two diseases is due to the fact that they constitute for most of the diseases both in
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developed and developing nations [105][136]. Studies have also shown a strong link between the
two diseases in terms of how one disease might influence the other. For example, The Framingham
study that was carried out for around 20 years showed the risk of diabetic patients developing
cardiovascular diseases to be twice as much as people without diabetes in men and thrice as much
in women [71]. Articles from the American Heart Association have stressed on the importance of
addressing both the diseases together as an act of prevention [55]. Although diabetes acts only as
an independent factor for heart diseases, the relatedness of the two diseases and the possibility of
finding interesting and new observations between them make them the natural choice for our study.
3.3 Learning Methods
This study investigates three algorithms, namely the co-regularized MVL, regularized MTL and
regularized MVMTL. We adopt the multi-view multi-task learning framework developed by Zhang
et al. Equation 3.1 denotes the predictive function for each task which is nothing but the average
prediction across all the views. For example, in our experiments we have three views and so V = 3
and for each task T , f (Xt) is the average prediction of the three views. Equation 3.2 represents
the objective function of MVMTL framework where the first term is the least square loss function
and the second term is the L2 regularization of the coefficients. The third term factors in the multi-
view component of the algorithm. µ is the coupling parameter that regularizes the disagreement
between different views. The fourth term accounts for the multi-task learning of the algorithm
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We derive the MVL and MTL algorithms from the above equation. By setting µ = 0, Equation
3.2 reduces to a regularized MTL framework. Similarly by setting γ = 0, the equation reduces
to a co-regularized MVL framework. We compare the performances of the three algorithms with
k-Nearest Neighbors and Random Forest.
3.4 Experimental Study
This section explains in detail the data sets, methods and the results obtained for multi-view and
multi-task learning algorithms and the comparison of its performance with other baseline methods.
3.4.1 Data Sets
We collected data from the Comparative Toxicogenomics Database (CTD) - a publicly avail-
able database that aims to interpret the effects of environmental hazards on human health [30].
The database has data that are manually curated as well as inferred chemical-gene, gene-disease,
chemical-diseases and gene-pathway associations to name a few. The curated associations are ex-
tracted from published literature and the inferred associations are ascertained from these curated
associations. For example, as shown in Figure 7.1 if there is a curated interaction between gene A
and disease B and a curated interaction between gene A and chemical C, then CTD establishes an
inferred association between chemical C and disease B.
Figure 3.1: A pictorial represented of curated and inferred associations in CTD
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The first data set consisted of five cardiovascular diseases namely Aortic Diseases, Heart Fail-
ure, Heart Valve Diseases, Arrhythmias and Heart Arrest. The second data set consists of four di-
abetic diseases namely Diabetic Angiopathies, Diabetic Cardiomyopathies, Diabetic Neuropathies
and Diabetes Mellitus. For each data set the diseases represented the different tasks for MTL. We
performed the following steps for each of the data sets to obtain the data-feature matrix and labels.
(i) We used the search tool in CTD to obtain information regarding the chemical and genes
associated with it.
(ii) From the search results, we filtered out only the records that have experimental validation
with direct evidence marked as therapeutic, marker/mechanism or both.
(iii) We pooled in this information from all the diseases in that particular data set to obtain a list
of unique chemicals and unique genes.
• Two other data files : gene-pathway associations and drug-enriched pathway associations
were downloaded from CTD.
(iv) The gene-pathway associations for the unique genes and the drug enriched pathway associ-
ations for the unique drugs involved in step (iii) were filtered out.
(v) If a drug and gene had an association in step (iii) and a gene and pathway had an association
in step (iv), we then related the drug and pathway to have an association.
(vi) For each of the diseases in a data set we represented its activity (label) with the unique drugs
with a +1 and an absence of activity with a -1.
Figure 3.2 and Figure 3.3 show the correlation of the diseases within the data set. For example,
if we consider Figure 3.2, the diagonal of the matrix plot represents the histogram of each of
the five diseases. The off-diagonals have the scatter plot of the (observation,value) pair and the
correlation coefficient which is the slope of the least squares fit.
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Figure 3.2: Label correlation of the cardiovascular diseases. AO - Aortic diseases, HF - Heart
Failure, VF - Valve Defects, AR - Arrhythmias, HA - Heart Arrest
For both data sets, a total of three views was constructed. The first view consists of chemical-
gene associations. The second view was an inferred association of drug-pathway obtained from
known gene-pathway associations and the third view consists of drug-enriched pathway associa-
tions. The features of all the three views were 1 for an association and 0 otherwise. The details of
the feature space and the total number of unique chemicals and the number of active compounds
for each disease has been tabulated in Table 3.1 and Table 4.1 respectively. For example, Aortic
and Heart Failure diseases have 20 and 198 active drugs respectively with a presence or absence of








Cardiovascular 114 161 278
Diabetes 62 140 265
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Figure 3.3: Label correlation of the diabetes diseases. AN - Angiopathies, CM -
Cardiomyopathies, NP - Neuropathies, ME - Mellitus
association with 114 unique genes, 161 inferred pathways and 278 enriched pathways.
3.4.2 Model Construction and Evaluation
N samples are chosen at random from both the classes of the data set to form the labeled samples
with roughly the same number of samples from each class. We then use five fold cross validation on
the labeled data set to generate training and test data to achieve better generalization performance.
The training data is further subjected to a five fold cross validation to choose the optimal model
parameters based on the F1 score. We use the same data across all the algorithms. For MVL, we
additionally sample some data for unlabeled data. Approximately N*3 samples are chosen to form
the unlabeled set. The above procedure is repeated 10 times and the average F1 score has been
reported.
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Table 3.2: Disease Data Characteristics where the no.of drugs represent the total number of drugs



















We use the F1 score to measure the performance of the classifiers.
P =
t p










where P and R represent precision and recall respectively. t p, tn, f p and f n specify the true posi-
tives, true negatives, false positives and false negatives respectively.
3.4.3 Performance comparison
A typical method of handling heterogeneous data or different views has been to form a feature
set with cardinality equal to the total number of features from all the views which in our case we
would combine the three feature spaces given by Equation 3.6. We call this the combined feature
space (CFS).
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Table 3.3: The average F1 score of the five learning methods on the cardiovascular data set
Methods
Diseases
Aortic Heart Failure Valve Defects Arrhythmias Heart Arrest
MTL 0.798±0.010 0.765±0.011 0.698±0.010 0.682±0.013 0.751±0.013
MVL 0.751±0.005 0.739±0.009 0.672±0.010 0.651±0.010 0.736±0.012
MVMTL 0.828±0.012 0.787±0.009 0.713±0.010 0.704±0.010 0.801±0.010
kNN 0.725±0.004 0.709±0.005 0.623±0.005 0.613±0.005 0.705±0.006






In order to compare the performance of the MVL and MTL algorithms we choose two baseline
algorithms that have been commonly used to build prediction models in cheminformatics namely
k-Nearest Neighbors (kNN) and Random Forests (RF). Except MVL and MVMTL algorithms, the
rest of the methods used the CFS.
3.5 Results
In this section, we present the results of our experiments performed on the two data sets. Table
3.3 shows the F1 score of the five cardiovascular diseases for the five learning methods explained
as before. For both our data sets, the number of views V was equal to 3 and the number of tasks T
was 5 for cardio diseases and 4 for diabetes respectively. The rows represent the learning methods
and the columns of the table represent each disease in the data set. The method with the highest
F1 score is printed in bold. For all the five methods, we have sampled the same number of positive
and negative samples since we are not concentrating on the data imbalance problem.
As a first observation, we can see that the three MT and ML methods perform better than kNN
and RF. Secondly, the trends across all the five methods are very similar. The higher or lower F1
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Table 3.4: The average F1 score of the five learning methods on the diabetes data set
Methods
Diseases
Angiopathies Cardiomyopathies Neuropathies Mellitus
MTL 0.628±0.008 0.623±0.006 0.753±0.008 0.652±0.007
MVL 0.618±0.004 0.577±0.002 0.721±0.010 0.637±0.006
MVMTL 0.652±0.006 0.639±0.007 0.784±0.010 0.658±0.003
kNN 0.592±0.005 0.559±0.005 0.660±0.004 0.570±0.005
RF 0.603±0.003 0.556±0.003 0.705±0.004 0.590±0.004
scores for each disease is due to the nature of data set itself and is not due to the learning methods
used. If we consider aortic disease, MVL performs better than kNN and RF. But this particular
task greatly benefits from MTL since the problem of low sample size can be overcome by learning
multiple tasks.
Similar to the previous plot, Table 3.4 represents the F1 scores of the four diabetes diseases.
Here again we observe consistent and better performance of the three methods in comparison with
RF and kNN. Typically in drug reurposing, the number of approved drugs are only a handful (low
positive sample) and hence multi-task learning techniques will help in alleviating this problem.
As we saw in the previous section, the different drug activity profiles among the diseases act as
additional data points when we adopt the MTL framework. This "extra" information helps in im-
proving the performance of a classifier.
As a general rule of thumb, heterogeneous features are generally combined to form a single
feature matrix. This was the method incorporated for all the methods except the multi-view learn-
ing framework. Out of the other four methods, two of them had the multi-task component and the
rest adopt different classifying strategies. In order to compare the performance of MVL with the
combined features space (CFS) within a similar framework we consider Equation 3.2 by setting
γ = 0. For the CFS method, the unlabeled samples will not have a significance since we have only
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Figure 3.4: Comparison of MVL vs CFS for cardiovascular diseases
one view and for MVL we consider the three different views.
The CFS scenario basically reduces the objective function to a ridge regression framework.
Figures 3.4 and 3.5 represent the F1 scores of MVL versus CFS for cardiovascular and diabetes
diseases which are represented by the orange and yellow bars respectively. We can clearly see
that MVL outperforms CFS although the margin is pretty close for some diseases like diabetes
cardiomyopathies and mellitus. For the majority of the diseases, MVL exhibits an improved per-
formance over the other method.
In order to show the advantage of using features from heterogeneous sources, the third set
of plots (Figures 3.6 and 3.7) show the comparison of F1 scores between MVL versus using
each feature space individually. The red bar denotes MVL and the yellow, green and blue color
bars represent the gene features, gene inferred pathway features and enriched pathway features
respectively. We observe that for a majority of the diseases, MVL method performs better than the
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Figure 3.5: Comparison of MVL vs CFS for diabetes diseases
Figure 3.6: Comparison of MVL vs learning on individual features for cardiovascular diseases
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individual features. We also notice the inconsistency of F1 scores among the three feature spaces.
Some features work better than the rest for each disease and we do not get a clear conclusion re-
garding which is the best. From the F1 scores we see that including additional information only
helps the classifier to predict better in all the cases.
Figure 3.7: Comparison of MVL vs learning on individual features for diabetes diseases
3.5.1 Statistical Significance
Testing for statistical significance emphasizes our belief in the hypothesis that multi-task and multi-
view algorithms perform better. This test is of importance especially when the difference in per-
formance of the classifiers in terms of their F1 scores is marginal. Tables 3.5 and 3.6 represent
the p-values obtained from the Wilcoxon test at the 95% confidence level for cardiovascular and
diabetes diseases respectively. The first two columns in the table represent the two methods that are
being compared and the third value represents the p-value obtained for the two methods using the
Wilcoxon rank test. Our null hypothesis H0 denotes that the algorithms are the same and our alter-
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nate hypothesis Ha argues that the algorithms are different. Since we chose the significance level
threshold to be 0.05, we reject the null hypothesis for a p-value ≤ 0.05. We performed the ranked
test between MVL and CFS-LR (represents single task learning), MVMTL and MVL, MVMTL
and MTL and lastly MTL and single task learning methods (kNN and RF). As an example, the p-
value associated with the testing of MVL and CFS-LR for cardiovascular diseases is 0.003 which
is ≤ 0.05 and so we reject the null hypothesis that the two algorithms are similar. From the tables
we can see that the suggested multi-task and multi-view learning methods significantly outperform
the other methods mentioned in our work. The scores reported here are based on the paired test
between two methods across all the T tasks.
Table 3.5: Wilcoxon ranked test among the methods for cardiovascular diseases






Table 3.6: Wilcoxon ranked test among the methods for diabetes diseases








In this empirical study, we explored a new direction of multi-view and multi-task learning al-
gorithms for studying drug-disease associations. These algorithms provide new avenues to be
explored for applications in cheminformatics where there is a need to utilize better computational
models in addition to another important aspect of integrating data in a useful manner. The ad-
vantages of using these methods are (i) unifying information from multiple resources (ii) learning
similar tasks to find new associations.
Multi-view learning has been the major study in this paper due to its powerful capabilities to ac-
commodate and extract useful information from multiple heterogeneous sources. With researchers
finding every extra piece of information crucial in understanding the behavior of drugs that would
help in understanding their associations, there is always a need to come up with methods that will
jointly learn these type of data. We showed that each feature space might perform better in some
occasions but the MVL algorithm consistently performs better thereby eliminating the need to as-
sess and iterate through the different feature spaces. For example, the drug-gene associations might
provide better predictive performance than the drug-enriched pathway associations. But it cannot
be affirmatively said that this would be the case. Also, other information could hold key clues that
might provide additional insight. The aim is therefore to maximize the predictive learning capa-
bilities of algorithm to effectively infer associations. The other biggest advantage of MVL is the
utilization of unlabeled samples. Since the learning involves minimizing the view disagreement on
the unlabeled samples, the algorithm proves to be powerful in capitalizing on this information.
Multi-task learning on the other hand has been adopted by the bioinformatics community
mostly in terms of modeling the multitarget property of drugs thereby improving the potential
to find new targets. Multitarget problems are dealt in a multilabel setting which differs from MTL
where similar diseases can be learned jointly. This setting is particularly useful when we have
limited number of samples to learn from. The "extra" information from the other tasks have shown
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to combat the problem of small sample sizes. In this study, we have shown that the joint learning
of related diseases benefit the overall performance of each disease. By combining the advantages
of MVL and MTL, the scope of integrating data as well as finding new potential targets is tremen-
dous and our statistical testing also reinforces our hypotheses. The MVMTL algorithm explained
in this study has the capability to also model task relationship which means it can form clusters of
similar tasks/diseases. As part of our ongoing research, the next step would be to integrate addi-
tional information such as drug-side effects relationships and also take advantage of cross-disease
information in order to further improve predicted drug-disease associations.
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Chapter 4
Weighted Multi-view Learning for
Predicting Drug-Disease Associations
4.1 Introduction
The paradigm of drug discovery has moved from finding new drugs that exhibit therapeutic proper-
ties for a disease to reusing existing approved drugs for a newer disease. The association between
a drug and a disease involves a complex network of targets and pathways. In order to provide new
insights, there has been a constant need for sophisticated tools that have the potential to discover
new associations from the underlying drugs-disease interactions. In addition to computational
tools, there has been an explosion of data available in terms of drugs, disease and their activ-
ity profiles. On one hand, researchers have been using existing machine learning tools that have
shown great promise in predicting associations but on the other hand there has been a void in ex-
ploiting advance machine learning frameworks to handle this kind of data integration. In this paper,
we propose a new learning framework called weighted multi-view classification that is a variant
of the well-known Multi-view learning framework. The primary motivation behind this method is
that, some descriptors help in prediction better than others. In a multi-view setting each type of de-
scriptor is represented as a view and we hypothesize that not all the views contribute equally to the
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final prediction. The proposed learning framework handles this discrepancy by learning weights
for each view and the final prediction is the weighted average of the prediction across all the views.
The effectiveness of the method especially to predict drug-disease associations is demonstrated by
comparing it with well-established methods on two different disease data sets.
4.2 Related work
The concept of drug discovery has been around for many decades during which a lot of research
in discovering new drugs has advanced the field of medicine by leaps and bounds [40]. The study
of interaction between small molecules and bio-molecules has gained importance since it forms
the crucial step in drug design [77][149]. However, the entire process of screening compounds
to getting the drugs approved is a very time consuming process and researchers turned towards
tools and methods that fastened this process. With the rapid accumulation of interaction data in
public databases such as BindingDB[87], KEGG[69] and Protein Data Bank[9], computational
tools gained popularity to exploit these large databases to build predictive models that helped
in speeding up the process [42][57]. Although computational tools do not serve as a substitute
to physical testing, they have been a powerful tool with the capability to short list the potential
candidates or unravel new insights that have previously been unknown [27].
4.2.1 Drug Repurposing
While discovering new drugs was actively growing, a new concept of reusing existing approved
drugs gained popularity for diseases for which it was not originally approved for [92]. Finding new
associations between approved drugs and new diseases is advantageous in terms of time, money
and other resources used during the development. The concept of one drug - one disease soon
moved to one drug - many diseases. One of the popular methods that has been used to achieve
reusing old drugs for new diseases is molecular docking [60][90] which takes in the structure of
compounds and targets and quantifies their binding. Computational tools and in particular machine
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learning algorithms have also played a vital role in establishing such new associations or have also
been used as a tool to rank drugs based on their potential to be reused [73][54]. One strategy that
was commonly adopted to find such new associations was to construct bipartite graphs between
the drug and target and quantify their interactions by a score [24][23]. These scores acted as the
labels that were used to build a predictive model or these interactions were modeled as a graph
network where the edges were weighted by the interaction scores.
4.2.2 Data Integration and Multi-view Learning
With an explosion of cheminformatics data available in the public databases [30][72] and there
has been a lot of excitement in utilizing the abundant information in better understanding the un-
derlying activities of drugs, the targets and pathways they modulate and also gain new insights
from these networks in terms of reusing approved drugs for newer diseases. In order to gain
usefully from this wealth of information, we need to resort to advance learning methods that
more effectively handle and integrate such high dimensional data with a relatively low sample
size [142][128][23]. The traditional practice has been to integrate data from different sources and
then utilizing an algorithm for either classification or drawing conclusions about associations and
interactions. As we integrate more information, there is a possibility of the number of dimensions
increasing drastically with the number of samples being relatively the same. In order to derive
the utmost benefit from the data, multi-view learning has shown promise in combating this issue
by considering each feature space as a view. One of the works that dealt with integrating data
from multiple resources includes the work by Yang et al, who used probability matrix factoriza-
tion to establish a drug-disease association by introducing a scoring method for each drug-tagret-
pathway-gene-disease chain [130]. Yu et al., showed the effectiveness of multi-view learning by
proposing a framework that mines biological text for gene prioritization [134]. Different vocab-
ularies were considered as different views and they showed that MVL methods performed better
than single-view learning. To summarize, each view or feature space might have an underlying
useful statistical property that needn’t be always preserved while combining them into a single
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view.
4.2.3 Weighted Multi-view Learning
Weighted multi-view learning in the literature has been limited to clustering methods. The initial
work by Tzortzis et al., explored this gap of unevenly weighting the views for clustering where each
view is expressed as a kernel matrix and the final learning is a weighted average of the kernels
[113]. This was further extended by Xu et al., who incorporated feature selection in addition
to weighting the views [126]. Jiang et al., went on to further weight the features too instead
of just performing a feature selection [65]. Denoising in multi-view learning has been another
popular method to handle errors in view data especially in image classification that could affect the
learning [141]. An image of a white siberian tiger could be wrongly labeled as a zebra and vice
versa. In such cases, denoising is a very important strategy to help in learning from such corrupted
data [140]. Our motivation is slightly different wherein we assume that not all views are equally
important and if there are noisy views, they must have a lower weight in the final prediction. Since
weighted multi-view learning has not been explored for classification/regression to the best of our
knowledge, we proposed the weighted multi-view learning for classification primarily motivated
by the fact that data integration in cheminformatics is highly desirable and needs a systematic
approach to handle multiple views and/or noisy data.
For our real data in this study, we have considered the cardiovascular and diabetes diseases
since they are two important diseases that are plaguing both developed as well as developing coun-
tries [136][105]. Studies have also shown a relation between the two diseases and how people with
diabetes are more prone to develop a cardiovascular disease [71]. The availability of data for these
two diseases in addition to their importance convinced us to use them for our study.
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4.3 Methodology
In this section, we propose a weighted multi-view learning framework that automatically learns
the weights of each view so that the final prediction is a weighted sum of the predictions of each
view as opposed to the average prediction across all the views.
4.3.1 Notations
In this paper, we used bold uppercase letters to represent a matrix (e.g X) and bold lowercase letters
to represent a vector (e.g. x). Greek letters are used to represent regularization parameters (e.g λ ),
simple lower and uppercase letters are used to represent scalars (e.g x, X). We use the subscript v
to denote a view. For example, if we have V views, Xv represents data X from view v where v ∈V .
All the vectors are column vectors unless specified.
4.3.2 Overview of the Learning Framework
We formally define the problem setting as follows. Let there be n labeled samples and let their
representation in view v be represented by Xv ∈ IRn×d and their labels be represented by y ∈
{−1,+1}n×1. We also assume that all the views agree upon the label for a particular observation.
The fundamental assumption of co-regularized multi-view learning is that the multiple views in-
volved in prediction are conditionally independent and each view is capable of generating their
own prediction model. The other major assumption is that there is class consistency of the labeled
samples across all the views. As shown in Equation5.1, the typically used co-regularized multi-
view learning considers each view to contribute equally. fv(Xv) represents the function learned on
the data from view v and the final prediction f (x) is the average of the prediction results from V
views. If we consider fv(Xv) = Xvwv and using the least square loss function, we have the objec-
tive function given by Equation 5.4. The first term is the least square loss function, the second term
represents the `2 norm of the model parameters while λ1 controls the strength of the norm. The
third term represents the view disagreement of different views controlled by the coupling parameter
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In our proposed weighted multi-view learning (wMVL), we weight the predictive function of





βv = 1 and βv ≥ 0. In addition to the model coefficients, the algorithm auto-
matically learns the weights thereby eliminating the need for any prior knowledge. By including
the constraints for the view weights, we obtain the objective function for weighted multi-view





















From Equation 4.3, we see that the proposed method is similar to a weighted least squares




v y and X′v = β
p
2
v Xv . For a new sample, the final prediction by combining all the views is










We solve the optimization problem of wMVL by alternatively updating wv and βv. The solution for
updating the parameters is obtained by computing the partial derivative of the objective function L
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Rearranging Equation (5.5) and setting it zero, we get a solution for wv.
(β pv XTv Xv +λ1 +µ(V −1)UTv Uv)wv = β
p






where Ft = β pv XTv Xv +λ1 +µ(V −1)UTv Uv




Taking partial derivative of the objective function L with respect to βv, we get the following
















































)2/(p−1) , p > 1 (4.12)
When p = 1, the weights are less than 1 given it’s constraint of summing to 1. We can get
βv =






In Equations (5.12) and (4.13), p is an exponential parameter that controls the sparsity of the
view weight vector β . The value of p can be chosen based on the number of views and it’s signif-
icance is further explained in the experimental section. The idea behind the weight vector is that,
the more useful a particular view is, higher is the weight assigned to that view.
4.4 Experimental Study
In this section, we explain in detail the data sets that have been used to test our hypothesis. We
used synthetic data as well as real cheminformatics data to study the effectiveness of the proposed
method. By performing these experiments, we analyze the role of the weight parameter β as well
as the parameter p that controls the sparsity of the weights.
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Algorithm 1 Weighted Multi-view Algorithm
1: Input: y, {Xv}Vv=1, {Uv}
V
v=1 λ1, µ , Nit , ε
2: Output: {wv}Vv=1, {βv0}
V
v=1
3: Initialize wv0 = 0 and βv = 1V for v ∈ [1 : V ]
4: for iter = 1 to Nit do
5: for v = 1 to V do
6: Compute Ft as given by Eqs.(7)
7: Compute St for every v′ 6= v as given by Eqs.(7)
8: end for
9: Compute wv := Ft−1St for each v ∈ [1 : V ]
10: Update βv using Eqs.(12) or (13) for each v ∈ [1 : V ]
11: ‖wv−wv0‖< ε & ‖βv−βv0‖< ε
12: break
13: wv0 := wv for each v ∈ [1 : V ]
14: βv0 := βv for each v ∈ [1 : V ]
15: end for
16: Return wv and βv
4.4.1 Data sets
4.4.1.1 Synthetic Data
To explain the fundamental working of the algorithm, we created a simple synthetic data set with
two views. The first view consists of samples from a normal distribution with each class having a
different mean and standard deviation. As shown in Figures 4.1a and 4.1b, the first view has the
two classes fairly separable and the second view is nothing but a noisy version of view 1. Both the
views had 60 samples in each class with 3 features for easy visualization. In the usual regularized
multi-view learning setup, the final prediction is the average of the two views (which means each
view will have a weight of 0.5) but we can clearly see that view 1 is more useful than view 2. Ac-
cording to our hypothesis, the proposed wMVL will learn a higher weight for view 1 as compared
to view 2 thereby weighting the prediction of view 1 more than view 2. The synthetic data is just a
simple model to show the effectiveness of the proposed method that can be extended to more views.
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(a) View 1 (b) View 2 - Noisy
Figure 4.1: The two views of the synthetic data. The circle and the triangle symbols represent the
two classes.
4.4.1.2 Drug-disease Data
For our real life data set,we wanted to apply the proposed method to predict drug-disease associ-
ations which was the driving motivation for wMVL. Data was primarily collected from the Com-
parative Toxicogenomics Database (CTD). It is a public database that works on establishing the
effects of environmental hazards on human health (insert ref). The database is manually curated
to reference direct as well as inferred relationships between drugs, genes and pathways to name a
few. The direct associations are curated from published literature and the inferred associations are
obtained from these curated information. Figure 7.1 illustrates the CTD database. For example if
Gene C and Drug A have a curated association and Drug A and Disease B have a curated asso-
ciation, then CTD defines an inferred relationship between Gene C and Disease B. In addition to
CTD, data was also extracted from DrugBank and PubChem which are two widely used databases
to extract the structures of drugs. We worked with two different disease data sets namely cardio-
vascular diseases and diabetic diseases. We chose multiple diseases to show the consistency of
our results. The cardiovascular dataset consisted of three diseases - Arrhythmias, Heart Arrest and
Heart Failure and the diabetic data set consisted of three diseases - Diabetes Mellitus, Diabetes
Neuropathies and Diabetic Cardiomyopathies.
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Figure 4.2: CTD
Both the data sets had three types of features/views namely: Structural descriptors, drug-gene
associations and drug-pathway associations. The following procedure was used to obtain our final
data-feature matrix:
(i) The CTD "Search" option was used to obtain all the chemical-gene of the diseases.
(ii) From the associations obtained, only the associations that had experimental validation with
therapeutic, marker|mechanism or both as direct evidence made it to the next stage.
(iii) For each data set (cardio or diabetes) the number of unique drugs and genes were pooled
together.
(iv) For these drugs, their pathway information was extracted from CTD.
(v) A drug-gene matrix was constructed with a +1 for an association and a 0 otherwise repre-
senting the drugs in the gene feature space.
(vi) A drug-pathway matrix was similarly constructed that formed the second feature space.
(vii) The structures for all the drugs were downloaded from DrugBank and PubChem.
(viii) In order to explore different features, we extracted the EFP fingerprints for the cardiovascular
drugs and 2D structures for the diabetes drugs.
(ix) The presence of an association of a disease and a drug was labeled as +1 and -1 otherwise.
Table 4.1 shows the number of active and inactive drugs for each disease.
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Figure 4.3: A representation of the four views of our drug-disease data set. Each view has N
samples where Xd ji represents sample i from view j. The total number of features for each data set
in the sum of d1,d2,d3 and d4
4.4.2 Algorithms/Learning Frameworks
The performance of our proposed wMVL is compared with five other learning methods/algorithms.
The primary method with which we study the effectiveness of wMVL is the co-regularized multi-
view learning method given by Equation (5.4). We also compare it with other benchmark single
view learning (SVL) algorithms such as k-Nearest Neighbors (kNN), Random Forest (RF) and the
Regularized Least Squares Method (Ridge). The general rule of thumb for handling heterogeneous
data by single task learning algorithms has been to combine them into a single feature space with
its cardinality equal to the sum of the features from all the views. In our case, we have three feature
spaces namely the structural features (ds), gene features (dg) and the pathway features (d p). All
of the four SVL algorithms combine the three spaces as given by Equation (4.14). We call this the






















Table 4.1: Disease Data Characteristics where the no.of drugs represent the total number of drugs
and the third column represents the active drugs for each disease
4.4.3 Model Construction and Evaluation
4.4.3.1 Model Construction and Selection
For the multi-view learning methods, ‘N’ samples are chosen at random from each class of the data
set to form the labeled samples. We sample them in such a way that both classes have the same
number of positive and negative samples since our focus is not the problem of data imbalance. We
also sample approximately N*3 samples to represent the unlabeled data in the MVL setting. The
labeled samples are then subjected to a five fold cross validation that results in training and test
data that helps in better generalization. The training data is further subjected to a five fold cross
validation to get the training and validation data sets that are used to select the model parameters.
For the single-view learning methods, we repeat the same process of obtaining our training, vali-
dation and test data sets as the MVL methods with the only exception being, SVL does not handle
unlabeled samples. The model parameters are selected through a grid search for each method. We
varied the number of neighbors for kNN from 3 to 9 in steps of 2. In the case of RF, the only
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parameter we considered was the number of features used to make the split and from the literature
we considered the square root of the total number of features as a good estimate for the number of
features.
4.4.3.2 Model Evaluation
We used the F1 score to measure the performance of the different classifiers.
P =
t p










t p, f n and f p are true positive, false negative and false positive respectively.
4.5 Results
In this section the results of our experiments performed on the synthetic and real life data sets
are presented. The performance of the learning methods have been analyzed and finally we have
included the results of statistical testing.
4.5.1 Performance Comparison
4.5.1.1 Synthetic Data Set
The synthetic data set consisted of 60 samples in each class with three features sampled from a
normal distribution. As explained earlier, we created two views with view 2 being a noisier ver-
sion of view 1. The objective function given by Equation (4.3) has an exponential parameter p that
is used to adjust the sparsity of the weights across the views. As the value of p is increased, the
view weights tend to become more uniform and might degrade the performance of the model. The
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choice of p depends on the number of views. As the weights become more uniform, the perfor-
mance of the classifier will be similar to that of the regular co-regularized multi-view learning.
p Value
Coefficients
View 1 View 2
p = 1 1 0
p = 1.5 0.7926 0.2074
p = 2 0.6577 0.3423
p = 5 0.5498 0.4502
p = 10 0.5307 0.4693
Table 4.2: The view weights learned by wMVL on the synthetic data set with two views
From Table 4.2 we see that when p = 1, based on Equation (4.13) the view with the lease error
will be assigned a weight 1 and the other views are given a weight 0. For our synthetic data we
know that view 1 can definitely make a better prediction than view 2 and hence they are given
weights 1 and 0 respectively. As we increase the value of p , the weights start getting more uni-
form among the views. But we can see that view 1 still has a marginally higher weight than view 2
when p = 10 which makes a very convincing argument given the two views. Table 4.3 summarizes
the F1 score of the of wMVL and MVL for the five values of p shown in Table 4.2. We can see
that when p = 1 only one of the views is involved in making a prediction and so the F1 score of
wMVL is not better than MVL. But as the value of p is increased, we can observe that the F1 score
of wMVL increases and performs better than MVL. We can see that for p values equal to 5 and
10, the weights are more uniform between the two views and yet due to the marginal difference in
weights, wMVL performs better than MVL.
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p Value wMVL MVL Ridge kNN RF
p = 1 0.983 ± 0.002 0.973 ± 0.019 0.965 ± 0.011 0.933 ± 0.003 0.826 ± 0.018
p = 1.5 0.989 ± 0.012 0.980 ± 0.006 0.973 ± 0.001 0.978 ± 0.011 0.913 ± 0.020
p = 2 0.992 ± 0.013 0.966 ± 0.004 0.958 ± 0.019 0.952 ± 0.008 0.934 ± 0.015
p = 5 0.991 ± 0.014 0.978 ± 0.010 0.966 ± 0.017 0.963 ± 0.005 0.897 ± 0.026
p = 10 0.988 ± 0.021 0.962 ± 0.009 0.964 ± 0.022 0.952 ± 0.006 0.907 ± 0.028
Table 4.3: Comparison of the F1 scores on the Synthetic Set
4.5.1.2 Drug-Disease data set
For the drug-disease data, we have four different views namely, 2D structure, fingerprints, pathway
and gene. The MVL would weight all these views equally or in other words, the weight for each
view would be 0.25. Tables 4.4 and 4.5 compare the F1 scores of the methods for the two diseases.
For wMVL, we had five different p values namely 1, 1.5, 2, 5 and 10. Due to space constraints
we present only the results for values 1, 2 and 5 since there was not a very huge difference in the
results between p = 1.5 and p = 2 and between p = 5 and p = 10. Figures 4.4a and 4.4b show the
weight distribution among the views for different p-values. The x-axis represent the p values and
the y-axis represent the value of the weights. As an example, if we consider the diabetes disease
data set, we can see that when p = 1, the 2D descriptors feature space/view is the one to result
in least error and hence a weight of 1 is assigned to that view while the rest are assigned a value
0 based on Equation (4.13). As the value of p is increased we can see the weight getting more
uniformly distributed across the views. We see a similar behavior of weight distribution for the
diabetes data set where the weights become uniform as p increases.
Tables 4.4 and 4.5 represents the average F1 scores of the five different methods and their error
variance within parenthesis for the two disease data sets. The method that performed the best is
highlighted in bold. As a first observation, we see that the data sets exhibit similar behavior in terms
of how the methods perform relative to each other. If we consider Arrhythmias as an example, we




p = 1 p = 2 p = 5
wMVL 0.736±0.0.11 0.780 ± 0.007 0.746 ± 0.019
MVL 0.752 ± 0.019 0.743±0.005 0.735±0.022
Ridge 0.744±0.009 0.729±0.005 0.724±0.003
kNN 0.715±0.011 0.720±0.009 0.716±0.006
RF 0.742±0.002 0.740±0.003 0.732±0.002
Heart Arrest
p = 1 p = 2 p = 5
wMVL 0.678 ± 0.0184 0.717 ± 0.0116 0.696 ± 0.0075
MVL 0.665±0.0593 0.672±0.0148 0.664±0.0667
Ridge 0.548±0.0132 0.571±0.0068 0.586±0.0741
kNN 0.654±0.0127 0.664±0.0109 0.653±0.0503
RF 0.636±0.0213 0.657±0.1000 0.640±0.0899
Heart Failure
p = 1 p = 2 p = 5
wMVL 0.704±0.0058 0.781 ± 0.0162 0.746 ± 0.0231
MVL 0.712 ± 0.0011 0.716±0.0030 0.728±0.0084
Ridge 0.685±0.0185 0.676±0.0083 0.663±0.0250
kNN 0.682±0.0053 0.692±0.0024 0.675±0.0081
RF 0.707±0.0066 0.706±0.0052 0.710±0.0035
Table 4.4: Performance comparison of the average F1 scores of the five methods on the cardiovas-
cular data set
learning methods which work on the CFS. Secondly, we see that when p = 1 MVL performs better
than wMVL due to the fact that wMVL utilizes only one view. With an increase in the value of p,
the F1 score improves with wMVL outperforming MVL. At p = 5, wMVL still performed better
than all the other methods. In the case of Heart Arrest, we see that wMVL performs better than
MVL even for p = 1 and we think this only by chance and instead of focusing merely on the F1
score, we think additional views add more insight to the underlying behavior of the drugs. For all
the diseases, p = 2 gave the best results for wMVL. Since we did not perform the experiments on
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the same set of observations for different p values, we have different values for the other methods
too and this should not be confused with the other methods being influenced by p. The exponential




p = 1 p = 2 p = 5
wMVL 0.587±0.051 0.617 ± 0.057 0.669 ± 0.061
MVL 0.592 ± 0.012 0.610±0.031 0.622 ± 0.020
Ridge 0.521±0.058 0.501±0.002 0.511±0.034
kNN 0.563±0.183 0.573±0.054 0.565±0.146
RF 0.554±0.037 0.572±0.058 0.580±0.104
Cardiomyopathies
p = 1 p = 2 p = 5
wMVL 0.552±0.054 0.603 ± 0.022 0.591 ± 0.088
MVL 0.567 ± 0.094 0.583±008 0.573±0.039
Ridge 0.529±0.015 0.534±0.076 0.513±0.053
kNN 0.546±0.119 0.543±0.077 0.553±0.091
RF 0.527±0.101 0.506±0.044 0.502±0.041
Mellitus
p = 1 p = 2 p = 5
wMVL 0.620±0.013 0.647 ± 0.053 0.668 ± 0.036
MVL 0.651 ± 0.052 0.642±0.054 0.650±0.029
Ridge 0.610±0.025 0.633±0.032 0.609±0.031
kNN 0.607±0.068 0.603±0.040 0.634±0.027
RF 0.624±0.0304 0.656±0.020 0.635±0.051




In addition to the F1 scores, we tested for statistical significance to emphasize that our proposed
method is significantly better than the other methods. Table 4.6 shows the p-values obtained from
the Wilcoxon paired test at the 95% confidence level for both the data sets. Due to space con-
straint, we are only presenting the results for the test based on the performance when p = 2 and
we randomly pick one disease from each data set although all the disease had similar results. We
compared wMVL with the rest of the four methods. Our null Hypothesis H0 is that the two algo-
rithms are same and our alternate hypothesis Ha argues otherwise. We reject the null hypothesis if
the p-value ≤ 0.05. From the results, we can see that wMVL significantly outperforms the other
methods compared in this study.
Cardiovascular Diabetes
Method 1 Method 2 p-value Method 1 Method 2 p-value
wMVL MVL 0.023 wMVL MVL 0.048
wMVL Ridge 0.007 wMVL Ridge 0.039
wMVL kNN 0.026 wMVL kNN 0.031
wMVL RF 0.015 wMVL RF 0.023
Table 4.6: Wilcoxon ranked test of wMVL with the other methods for the two disease data sets
4.6 Conclusion and Future Work
In this paper, we proposed a method called weighted multi-view learning that is similar to a co-
regularized multi-view learning framework but weights each view differently. The primary moti-
vation for this work was the need for a framework in cheminformatics that could handle data from
multiple sources but at the same time weigh useful data more than noisy data. When there is an
increase in the number of features due to additional information, the complexity of the model can
drastically increase thereby decreasing the learning model with low sample size. MVL addresses
this issue effectively by handling each feature space individually by keeping a relatively low model
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complexity but learns useful information from other views. From our experimental results on both
synthetic and real life data, we show that wMVL performs better than the co-regularized MVL and
single view learning methods. The test for statistical significance further emphasizes that wMVL
has a performance capability significantly better than the other traditionally used methods. The
algorithm’s capability to learn the view weights without the need for prior information makes it all
the more attractive and easier to use.
As part of our ongoing work, we are looking to extend the wMVL learning framework to handle
multiple tasks since we know that multi-task learning enhances the overall performance of all the
tasks when related tasks are learned jointly. In our case we would extend this framework to learn
diseases that are related to each other in terms of their properties or their drug activities. We believe
that in learning multiple tasks, we overcome the small sample size problem and also help in better








Multi-task with Weighted Multi-view
Learning for Predicting Chemical-Target
Interactions
5.1 Introduction
The study of interaction between small molecules and biomolecules, especially proteins has gained
importance in the field of design since it forms a crucial step in drug development [3][8]. There is
a fast accumulation of protein-chemical interaction data in the public domain such as PubChem,
ChEMBL and Protein Data Bank. It was estimated that only 1% of chemical information is stored
in public domain [32]. This scenario has changed over the last few years where the accumulation
of digitalized data on chemical structures, interaction of chemicals and proteins and chemical ge-
nomics has seen an exponential growth. As of October 2016, PubChem has around 1.2 million
bioassays, 100 million compounds and 300 million substances. ChEMBL which contains chemi-
cal compounds and their bioactivities has around 11 thousand targets, 2 million compounds and 14
million activities. Computational tools for studying PCI has never been a way to replace physical
experiments but a way to support them in drug discovery. With the availability of databases con-
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taining a large amount of structures and activity information about compounds, researchers have
the advantage of exploiting these huge data to develop new methods to effectively predict PCI. The
use of machine learning techniques has been drawing great interest in predicting such interactions.
CPI has two important characteristics that make it challenging for the use of machine learning
techniques. Firstly, the distribution of known protein interaction data is highly skewed. Secondly,
CPIs are very sparse. Bioassays have very less active compounds out of the hundreds of thousands
of compounds screened. Establishing a chemical-protein interaction pair has become a key chal-
lenge in drug discovery. Since physical experiments have known to be extremely time consuming,
ML techniques have been utilized to develop computational methods for CPI prediction.
5.2 Related Work
The research about chemical-target interactions has been around for many years now [3][8], yet
the cheminformatics community is constantly on the lookout for tools that help in speeding up the
process. Due to the fact that the initial drug-screening process is time consuming phase and very
pricey [? ], researchers brought in the idea of utilizing computational tools that helped in narrowing
down the search for potential drugs from hundreds of thousands of molecules to a few thousand
molecules (References). This exploitation of computational methods has shown to bring about an
improvement in drug design in terms of time and efficiency in identifying potential small molecules
and indirectly also reducing the costs involved. Identifying chemical-target interactions are vital in
terms of: 1) finding direct relationships between a drug and a target [12]. 2) identifying side effects
or adverse drug reactions [139]. 3) establishing a relationship between drugs and diseases [20]. 4)
Re-purposing an approved drug to modify a different target which in turn might be therapeutic for
a newer disease [24].
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5.2.1 Data Integration
Additional data or extra information has always been seen as a boon while trying to gain knowl-
edge. With an explosion of data in the public domain, it is desirable to utilize them to improve the
quality of data used in developing prediction models. Most of the databases for computational bi-
ology specialize in certain aspects. For example while one database might focus on the side-effect
profiles of drugs [76], another database might contain data about their pathway profiles [68]. Uti-
lizing both these databases would prove to be advantageous. A classic way to integrate data from
multiple databases or sources is to combine them into a single feature space [23][128]. Although
this has been a typical way to fuse heterogeneous data, it might not be a good idea due to the fact
that the integration might lead to a very high dimensional data while the sample size remains the
same. The other key drawback of such a practice is that, each information space might have an
underlying statistical property that might not be preserved while integrating them together. On
the other hand, databases can also "teach" or "learn" from each other by acting as supplementary
information. The solution for the above stated problems has been addressed by multi-view learn-
ing where the views learn from each other [95] on a set of unlabeled samples. In a co-regularized
setting, each view has its own model and the views try to minimize their disagreement about the
label on a set of unlabeled samples.
5.2.2 Learning Related Targets
Multi-task learning (MTL) has been researched for a long time now for various applications
[21][10][53] including computational biology [139][11]. The fundamental assumption of MTL is
that when similar tasks are jointly learned together, their overall performance is better than learn-
ing each individual task separately [18]. This concept has been used in cheminformatics where
similar targets and their drug interactions have been studied [96]. Xing et al., proposed a kernel
based MTL approach to model target similarities to improve SAR models. Jintao et al., [139]
studied MTL for chemical-protein interaction using a task regularized framework. Similar studies
include using MTL for HIV screening [11], prioritizing disease genes [93] and discovering targets
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for Alzheimer’s [47]. On the other hand, the multi-target scenario where a drug interacts with
multiple targets has been handled as a multi-label problem where a classifier is used to train in a
"one-versus-rest" binary setting [24]. The other main advantage of MTL is that, the skewed nature
of class samples is alleviated by learning from samples of similar tasks.
5.2.3 Multi-task Multi-view Learning
Combining the advantages of both multi-task as well as multi-view learning has not been explored
to its full potential in the field of cheminformatics, however, preliminary studies show a promise
in exploiting this framework [20][139]. Zhang et al., used the multi-task multi-view framework to
predict adverse drug reactions (ADRs). A quantitative relationship between drug structures, drug-
protein profiles and drug-ADRs (multi-view) was studied by learning multiple ADRs together
(multi-task). Similarly Chandrasekaran et al., performed an empirical study using the MTMVL
to predict drug-disease associations by learning related diseases as well as combining data from
varied sources results and have shown the effectiveness of this framework. But one underlying as-
sumption in this has been the assumption that each source of data contributes equally to the learn-
ing process. This assumption might sometimes be too strong. In order to mitigate this problem,
weighted multi-view learning (wMVL) methods have been proposed where each view is weighted
based on its prediction power. Initial weighted multi-view learning concentrated on clustering
methods that helped in learning the view weights as well as the model parameters without any
prior knowledge about the views. Chandrasekaran et al., further proposed a weighted multi-view
framework for classification and demonstrated its effectiveness in predicting drug-disease associ-
ations. In this paper, we propose a method called Multi-task with weighted Multi-view Learning
(MTwMVL) framework that leverages the advantages of wMVL as well as multi-task learning.
The proposed method is effective in the following ways:
• The multi-view learning part takes care of the high dimensional data that is accrued due to
the fusion of multiple sources.
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• Weighting the views based on their prediction power further improves MVL.
• The multi-task component of the framework addresses the problem of low sample size by
learning related tasks jointly. The skewed nature of cheminformatics data is a major chal-
lenge utilizing machine learning tools and MTL overcomes this hurdle.
5.3 Method
In this section, we propose a multi-task with weighted multi-view learning (MTwMVL) framework
that jointly learns similar related tasks and learns from multiple views in a weighted way where
the learning framework automatically learns the weights of each view for each task. The final
prediction for a given task is the weighted sum of the predictions of each view as opposed to the
average prediction across all the views.
5.3.1 Notations
In this paper, we used bold uppercase letters to represent a matrix (e.g X) and bold lowercase letters
to represent a vector (e.g. x). Greek letters are used to represent regularization parameters (e.g λ ),
simple lower and uppercase letters are used to represent scalars (e.g x, X). We use the subscript v
to denote a view. For example, if we have V views, Xv represents data X from view v where v ∈V .
All the vectors are column vectors unless specified.
5.3.2 Overview of Learning Framework
Let n be the number of labeled samples in view v and task t, denoted by Xvt ∈ IRn×d and y ∈
{−1,+1}n×1 be their corresponding labels. We represent the unlabeled data of task t and view v
as Uvt ∈ IRn×d . For a given task t, the prediction on a sample xtt is given by the average prediction









For our proposed method, we define the prediction for task t as the weighted average of all the






v(xv) = β vt Xvt wvt (5.2)
The objective function of multi-task multi-view algorithm proposed by Zhang et al., is given
by Equation 5.3. The first term is the weighted least squares error of the models on each task
and view and the second term regularizes the model coefficients for each view of a given task.
For a particular task, the third term minimizes the view disagreement between two different views
controlled by the parameter µ . Minimizing this term enforces the views to agree with each other on
the unlabeled samples as much as possible. Similarly, the fourth term minimizes the disagreement


















∥∥∥Uvt wvt −Uv′t wv′t ∥∥∥2 + γ2 T∑t 6=t ′∥∥wvt −wvt ′∥∥2
(5.3)
We modify the above objective function to accommodate the weighting of the views by intro-
ducing β vt . For a view that gives low error, a higher weight is assigned and for a view with high





β vt = 1 and β
v
t >= 0. Similarly we also enforce that for a given task, the view
weights should be similar as given by the fifth term in Equation 5.4. We aim to jointly minimize



































































t ′ = D













The above sets of equations solve for each wvt jointly by computing the sets of linear equations.
We similarly solve for the view weights by differentiating Equation 5.5 with respect to each β vt
and setting it to zero.
∂F
∂β vt
= (yt−Xvt wvt )2β vt +λ3(T −1)β vt −λ3 ∑
t ′ 6=t
β vt ′ +λ2 (5.7)





β vt ′ −λ2
(yt−Xvt wvt )2 +λ3(T −1)
(5.8)




β vt = 1, we get the following equation where




























(yt−Xat wat )2−λ3(T −1)
) (5.11)









(yt−Xvt wvt )2−λ3(T −1)
(yt−Xat wat )2−λ3(T −1)
)
(5.12)
Equations 5.6 and 5.12 give the update rules for the model co-efficients and the view weights
respectively. Initially, all the views are weighted equally (1/V) and the weights are automatically
learned using the update rule. The advantage of this method is that it eliminates the need for a prior
knowledge of the view weights.
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Algorithm 2 Multi-task with Weighted Multi-view Algorithm






v=1,t=1 λ1, µ , Nit , ε











V for t ∈ [1 : T ] and v ∈ [1 : V ]
4: for iter = 1 to Nit do
5: for t = 1 to T do
6: for v = 1 to V do
7: Compute Ft as given by Eqs.(7)
8: Compute St for every v′ 6= v as given by Eqs.(7)
9: end for
10: Compute wvt := Ft−1St for each v ∈ [1 : V ]
11: Update β vt using Eqs.(12) or (13) for each v ∈ [1 : V ]
12:
∥∥wvt −wv0t0∥∥< ε & ∥∥β vt −β v0t0 ∥∥< ε
13: break
14: wv0t0 := w
v
t for each v ∈ [1 : V ] and t ∈ [1 : T ]
15: β v0t0 := β
v
t for each v ∈ [1 : V ] and t ∈ [1 : T ]
16: end for
17: end for




Data was collected from ChEMBL database [51] that contains manually curated information re-
garding bioactive molecules that have the potential to be drugs. We picked two subfamilies from
the GPCR family namely Dopamines and Histamines. For the Dopamines we chose D1, D2 and D3
receptors and for Histamines we chose H1, H2 and H3 receptors. We first search for the target (e.g.
Dopamine D1) and download their bioactivities. The files contained information of the chemicals
that were tested against the D1 receptor. As a preprocessing phase, we then adopted the following
criteria to filter the raw data to obtain the final dataset.
1. Records with a value of 1 for the pot/duplicate field were removed.
2. Only records from the B,A and F assays were retained.
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Figure 5.1: Label correlation of the three dopamine receptors - DRD1, DRD2 and DRD3
3. Records with a molecular weight < 150 and > 900 were filtered out.
4. chemicals that did not have a confidence score of 9 were removed further.
5. All the chemicals with an absence of pKi value were filtered out.
6. Some chemicals had multiple activities reported. Samples that had a PChEMBL value that
differed by more than 1 were excluded and the average values of the remaining records was
used as the PChEMBL value for that particular chemical.
7. Chemicals with a pKi value <=5 were counted as active interactions (label +1) and a pKi >
5 was accounted as an absence of interaction (label -1) with the target of interest.
Figures 5.1 and 5.2 are the correlation plots of dopamine and histamine receptors respectively.
The correlation was calculated for the proteins within their families. Just for the correlation study,
we filtered out the chemicals (if any) common to all three receptors (eg: DRD1, DRD2, DRD3)
and calculated the correlation on their labels. The dopamine receptors had 201 chemicals common
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Figure 5.2: Label correlation of the three histamine receptors - H1, H2 and H3
between DRD1, DRD2 and DRD3. Similarly the histamine receptors had just 10 chemicals com-
mon between H1, H2 and H3.
5.4.2 Feature/View Construction
We constructed three views for each compound in the data set. Alexious et al., [74] showed the po-
tential of the molecular descriptor space capturing different properties of a compound. In reference
to that work, we considered three types of molecular descriptors - 2D structural features, Extended
Circular Fingerprints (ECFP) and pharmacophore based descriptor GpiDAPH3 and hence each tar-
get had three views. The 2D descriptors had 192 features, the ECFP descriptors had 1024 features
and the GpiDAPH3 descriptors had varying number of features for each target in the subfamilies.
We modified the third pharmacophore view by standardizing across targets within each subfamily.
If two or more features had greater than 95% correlation, we represented the entire group with a
randomly picked feature from the group. The 2D descriptors and the pharmocophore descriptors
were calculated using MOE software [116]. For e.g. if D1 had a1 and a2 pharmocophore features,
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Table 5.1: The table represents the total number of chemicals for each target and the number of








DRD1 505 16 489
DRD2 2514 53 2461
DRD3 1715 41 1674
H1 424 15 409
H2 95 8 87
H3 2239 18 2221




Dopamines 192 1024 6128
Histamines 192 1024 4879
D2 had a3 and D3 had a1, we constructed a binary matrix with a1,a2 and a3 as the three features
for view 3 of Dopamines and marked a +1 for compounds with a particular feature and 0 otherwise.
5.4.3 Model Construction and Evaluation
We choose N samples at random from each task by making sure we select equal samples from
both classes since we are not studying the effects of class imbalance. In addition to the N samples,
we additionally choose random samples to form the unlabeled samples for MVL. The size of the
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Figure 5.3: A graphical representation of multiple tasks and multiple views. Each view has N
samples and each view has d1, d2 and d3 number of total features respectively. A sample from
view 1 and task 2 is represented as x12
unlabeled set is generally N ∗ 3. We subject the data to a five fold cross validation to obtain the
training and test set. We further perform a five fold cross validation on the training set to get the
training and validation sets. We use the training and validation sets for a grid search to obtain
the optimal hyperparameters for each algorithm. This entire process is repeated 10 times and the
performance of the classifiers are reported as the average of all the 50 models.
The F1 score is used to measure the performance of all the models. P and R denote the precision



















MVMTL λ1, γ , µ
wMVL λ1, λ2, γ , µ
MTwMVL λ1, λ2, λ3,γ , µ
Ridge λ1
5.4.4 Performance Comparison
We compared the performance of the proposed MTwMVL method with the following methods.































∥∥∥∥2 + λ12 V∑v=1‖wv‖2 + µ2 V∑v 6=v′
∥∥∥Uvwv−Uv′wv′∥∥∥2 (5.17)
3. By introducing a weighting parameter β to the co=regularized MVL, we get the objective


























4. By not introducing β and setting λ2 and λ3 to 0, we get the multi-task multi-view learning


















∥∥∥Uvt wvt −Uv′t wv′t ∥∥∥2 + γ2 T∑t 6=t ′∥∥wvt −wvt ′∥∥2
(5.19)
5. By setting γ and µ to 0 and by not introducing β , the function reduces to ridge regression that










In this section, we test the proposed method with two datasets from ChEMBL and compare its
performance with the other algorithms explained in our experiment section. For all the algorithms,
we calculate the F1 score as a measure of the classifiers’ performance. For both the Dopamine
and Histamine data, the number of tasks T is 3 and the number of views V is 3. Tables 5.4 and
5.5 show the F1 scores (and the variance) of our experiments. The rows of the tables represent the
learning methods and the columns represent the targets. For the single-task single-view algorithm,
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we chose ridge regression since the base classifier is similar to the proposed method and it is only
fair to compare learning methods that are similar. The method with the highest F1 score with re-
spect to each target is represented in bold.
We first take the dopamine data as an example to discuss the results given in Table 5.4. As a
first remark, we see that Ridge regression has the least F1 score and MTwMVL has the highest F1
score. This can be attributed to the fact that Ridge puts together all the three feature spaces and
considers them as a single view. With low sample size and high dimensionality, the performance
of the classifier could be affected. Secondly, we observe that by adopting a multi-view framework,
the F1 score is considerably higher. Since the framework considers each feature space as a separate
view and the views learn from each other, the performance of the classifier is better than Ridge.
The performance of the MVL is further improved by wMVL which weights the three views based
on their prediction power. Instead of weighting the three views equally, wMVL learns a weight for
each view by assigning highest weight for the view with least error and least weight for the view
with the highest error. Both the methods however still learn each of the targets separately.




Ridge 0.602±0.048 0.592±0.089 0.376±0.024
MVL 0.715±0.041 0.683±0.053 0.476±0.060
wMVL 0.735±0.021 0.716±0.039 0.502±0.067
MTL 0.769±0.053 0.752±0.025 0.747±0.049
MTMVL 0.770±0.012 0.783±0.003 0.762±0.038
MTwMVL 0.823±0.022 0.830±0.015 0.787±0.027
Observing the F1 score of MTL, we see that the F1 score is better than the MVL learning
methods. This is because, as shown in Table 5.2, the number of chemicals having a true positive
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Ridge 0.616±0.056 0.629±0.002 0.510±0.005
MVL 0.693±0.043 0.675±0.010 0.581±0.027
wMVL 0.704±0.053 0.714±0.024 0.600±0.016
wMTL 0.748±0.029 0.732±0.035 0.655±0.042
MTMVL 0.776±0.022 0.768±0.051 0.688±0.37
MTwMVL 0.817±0.023 0.794±0.017 0.728±0.026
interaction with the targets is very low. Since the main advantage of MTL is to learn similar tasks
together, the tasks utilize the positive interactions from the other two dopamine receptors too. This
improves the performance of the classifier as compared to Ridge. The increase in the F1 scores
of all the three dopamine receptors between Ridge and MTL proves that multi-task learning is a
promising method when individual tasks have very low positive or negative (or both) sample sizes.
By combining the advantages of MTL and MVL, the MTMVL performs better than if both of them
were applied on the data separately. In spite of learning from related tasks, the number of features
can still be very high when all the features are combined into a single view. As a result, we see that
MTMVL performs better than Ridge, MVL and MTL methods. Lastly, the proposed method that
extends the MTMVL into a weighted framework improves the performance of the model further
by combing wMVL and MTL.
Similar to the dopamine data set, the results for the histamine data exhibit similar trends in the
performance of the six different learning methods. The Ridge classifier has the least F1 score and
MTwMVL has the highest F1 score, thus showing the efficiency of our method over other relevant
algorithms. In all of our experiments, if a particular iteration gave an NaN as the F1 score, we
ran an extra iteration to replace the NaN values. Similarly when the experiments were performed




In this paper, we proposed a multi-task with weighted multi-view framework to predict the in-
teractions of chemicals and targets. The motivation behind weighting the views comes from the
fact that different views can have varied predictive power. The second motivation is that, as more
descriptors/information are used to represent the compounds, the dimensions can drastically in-
crease for relatively the same number of samples. In order to mitigate this problem, multi-view
learning partitions each feature space as a view. On the other hand, multi-task learning addresses
the problem of low sample size by jointly learning similar tasks. The proposed method proves to
be a unified framework that addresses both the problems stated above. Our systematic comparison
of the performances of the proposed method and relevant learning algorithms show the promise
of MTwMVL. As a part of our future work, we would extend the current method to handle het-
erogeneous tasks. Similar tasks would share parameters while dissimilar tasks would not have a
common representation. Multi-task learning has already been used to tackle the problem of au-
tomatically learning task relationships. The other factor that would be incorporated is to handle
missing values. Some feature spaces might have missing values and improvising the MTwMVL to
handle missing data would be an advantageous improvement.
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Chapter 6
Literature Survey on Truth discovery
6.1 Introduction
In the age of information burst, we have voluminous data available across different platforms.
Analysing such data for building recommendation systems , decision making or to build predictive
models has been going on for many years now. The challenge recently has been the inconsistency
of facts/truths regarding a certain object across multiple platforms. For example, data is available
across many mediums such as Twitter, Facebook, Instagram (or other social networks), forums
(such as Quora or Stack exchange) and blogs. When information from different sources are aggre-
gated to make a decision or build products, the truth needs to better detected. For example, a user
on Facebook might have their location as "California" but have their location on Twitter as "Texas".
Only one of these two could be true in most cases unless there is an exception. In the presence
of a conflict, the performance of a model built on such data is pushed to be poorer which is not
desirable. In order to overcome this discrepancy, finding the truth about the conflicting data has
gained importance in the last few years. It is easy to discard conflicting data but sometimes useful
information from that source might be lost. On the other hand, the most common and intuitive way
to resolve this conflict is to take a majority voting or averaging. The main drawback of adopting
such a method is that sources might copy from each other or there might be just one source with
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the most recent update about the truth and is more valuable than the other sources and hence voting
or averaging might disregard such data. Another drawback is that in a voting/averaging process,
every source is given equal weightage. Due to this, the effect of quantity of the data overtakes
the quality of the truth to be detected. To combat these issues, truth discovery or truth finding has
gained rapid popularity in the aim to find fact(s) about objects [36][39][50][81][85][144][132]. Li
et al., have done a very exhaustive literature survey on truth discovery methods addressing their
various facets.
6.2 Facets of Truth Discovery
6.2.1 Common Strategies
When multiple sources provide different values for an object, the common strategy used to find
the most likely value would be to take a majority voting or the average in the case of continuous
information. As discussed earlier, if there are multiple sources claiming a false value, the majority
voting would result in declaring that as the true value. The strength of truth discovery methods
lie in the fact that they have the ability to output a minority value as the truth. The main principle
that is followed is to estimate the reliability of the sources based on the data given. The reliability
of a source is estimated based on the values for all the objects and properties it provides and each
source is assigned a weight ’wi’, where i = 1 : s, the total number of sources.
There are many challenges associated with truth discovery which has given rise to a lot of
different methods. Each method has addressed different challenges involved in truth discovery.
Among the different aspects of truth discovery, a few of them are in terms of the input data, the
appropriate assumptions about the output/truth, the possibility of a correlation or some sort of
relationships between the sources. We summarize a few aspects here to show our understanding
and perspective of the field.
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6.2.2 Input Data and Preprocessing
The input data from different sources need preprocessing most of the times. If all the sources
have the same value claimed about an object, it indicates a lack of conflict and so the true value is
clearly established. These records are generally removed and it has also been shown that removing
these records in fact improves the effectiveness of the methods [144]. One method however over-
looks this and assumes that there might be other unknown outputs [102]. The input data across the
sources are mostly in different formats. Hence it is essential to standardize them since the truth in
order to compare the sources [84]. For example, some sources might list name in a "last name, first
name" format and some other might include the middle name too. In terms of numeric features,
one source might have it in different units compared to the rest.
Data collected from certain sources might contain several records for the same object. This is
common in platforms that are open to public can alter the information. In these cases, the data with
the latest time stamp is considered although this can come with its own problems. In the absence
of a time stamp, a well deviced rule should be used [104]. Most of the work deals with static data
but in some scenarios, data is dynamic and changes over time. This means that the model has
to be recomputed each time which might not be feasible. Some methods address this and have
developed methods for streaming data [85][118]. A new challenge in terms of extracting data has
been to mine data from unstructured databases. Typically, structured data from relational databases
have been a lot more easy to handle [50][36] but they seem to lack some extra information that
unstructured data provide. [34][91].
Most of the methods address truth discovery based on the assumption that the ground truth
is not known any of the objects. Although this might be true in most cases, there has been a
branch of work where the authors consider that there is some amount ground truth that is known
[133][88][38]. With the help of the labeled objects, truth discovery is approached in a semi-
supervised setting. It has been shown that a few labels go a long way in helping learn the truth of
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the unlabeled objects.
6.2.3 Estimating Source Reliability
A big portion of research in truth discovery is with respect to finding source reliability. The first
line of thought is that sources are totally independent in collecting information about an object.
This implies that the truth would be the same across the sources but the false data would be dif-
ferent depending on what basis and condition each source collected the information [50][82][133].
The second type of methods assume that the source presents the truth on all the objects with the
same degree of reliability or with the same probability. Although this has been shown to be true in
most applications, it might be a strong assumption for certain fields [132][144]. Unlike previous
assumptions, some methods learn multiple reliability scores for each source. Gupta et al., demon-
strated that the objects could first be clustered and a reliability score could be estimated for each
object set [56]. As pointed out earlier, it might be too strict to assume that a source is reliable for
all the attributes of an object. Yin et l., estimated reliability scores separately for each attribute
thereby resulting in multiple reliability scores for a source [133].
A lot of methods in truth discovery assume that sources are not independent and have some
level of dependency on each other [35][36][37][107]. When sources copy from each other, they
are also bound to have the same false information regarding the objects. It is useful to detect
this copying relationship between sources which would capture the common errors between them.
This would however not be possible if sources copy from a correct source. Each source has its own
information plus some copied information. Dong et al., used a Bayesian inference approach to di-
rectly detect the copying relationship [36] where an iterative method is used to update the copying
relationship and the truth alternatively. In methods dealing with dynamic data, Dong et al., used
a Hidden Markov Model to capture the copying relationship [37] by using snapshots of data and
the output is an evolving value of the truths. Pochampally et al., added a different perspective to
model the source dependency by studying the correlations among them [103]. The method models
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correlations using joint precision and joint recall and the probability of an observation to be true
is inferred using Bayesian analysis. In some exceptions like the work pointed out by Wang et al.,
the sources cite where they copied from [119]. For example, a news website could reference their
information from a blog or another news portal.
A pitfall in estimating source reliabilities is the way in which they are initialized as a starting
point. Most of them assign equal weights to all the sources as a common way to begin the es-
timation but this doesn’t prove to be effective always. Assigning equal weights would result in
the truth being updated as the majority of the values claimed by the different sources. This works
when the majority of the values represent the truth. If majority of the sources contain false values,
assigning equal view weights would not make sense. To overcome this, some researchers make use
of a small set of labeled data [133]. Some others model source similarity as a prior knowledge so
that the initial point of estimation is more accurate [80]. Unlike what was expected, studies show
that more sources do not always and necessarily mean better capability to learn the truth and in
fact some corrupt sources might degrade the performance [38]. Sarma et al., proposed a method to
select a subset of sources based on cost constraints formulized as an optimization problem [107].
A different perspective to this whole argument was made by Li et al., who showed that a bad source
also contributes towards truth discovery by setting negative weights to them. This in turn with a
high probability infer what is wrong information. The truth about an object was in most cases
considered independent in terms of its attributes but this need not be true always. For example, the
date of birth and age could be related and need not be considered independent and this knowing
relation could improve truth finding [102].
The relation between objects could also be a temporal or a spacial one. Another important
challenge in truth discovery is the type of data present. Invariably the data falls into one of the two
categories namely, categorical or numerical. Most of the methods are capable of handling only one
type of data. Li et al., [82] proposed a unified framework which could work with heterogeneous
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data to discover the truth. The authors use appropriate loss functions and formulized the truth of
a object as the weighted sum of the objects from each source. The weights of the sources and the
truth were alternatively optimized.
6.2.4 Assumptions
Having discussed about the input data and source reliability, we now turn our focus towards the
assumptions and strategies adopted in the development of truth discovery in terms of their claimed
values and output. Some methods assume that every object has only one true value and if the ob-
ject votes for a value, then it opposes all the other values. This strategy of complimentary voting
was demonstrated by [50][145]. This might not be true always and so some work propose the
possibility of multiple truths [103][145]. For example, a course might be lectured by more than
one professor or an album might have multiple singer. Under these assumptions, instead of just
the source accuracy, precision and recall values were also used to detect the multiple truths. Zhi
et al., put forth an interesting idea of including "unknown" as a common truth to all the objects
apart from truth claimed by the object [146]. This helped scenarios in which there was no truth.
It was impacted the optimization of finding the truth if the constraint was the relation between the
sources. With the addition of this unknown truth, the sources has a relation if there was no truth
common between them.
Yin et al., demonstrated the need for interpreting the claimed values [132] in a more relaxed
setting. For example, if source 1 claimed a value of Mr. X’s property as 3 million, source 2 claimed
a value of 3.1 million and source 3 claimed a value of 8 million, then source 2 is considered
trustworthy with a high probability given that source 1 is true whereas the value claimed by source
3 is false. Some methods output a label for each truth claimed by the sources. They output either a
true or false label for each truth [144]. Some other methods output a score for each claimed value
and the truth is deduced using post processing rules. Most or all of the methods use accuracy as a
performance measure to arrive at the truth of an object. While accuracy is common for categorical
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data, mean square error is widely used for continuous data.
6.2.5 Templates of Popular Frameworks
6.2.5.1 Notations
The common jargon and definitions used by most researchers in this field is as follows: We have
different sources ’s’ that contribute some information or value ’v’ about an object ’o’. The truth of
an object is ’v∗’. Each source might be given a weight ’w’ that indirectly tells us the reliability of
a source. Hence an observation is an object ’o’ from source ’s’ and that assigns a value ’v’ as the
information of the object. Each object can have more than one property for which the truth needs to
be determined. For example, let us say that we want to determine the truth about a person’s height,
weight and home location, there are multiple sources that provide this information. We could for
simplicity consider the DMV and hospital records as two sources ’s1’ and ’s2’. The object here
is the person and we have to determine the truth for three properties namely, height, weight and
home location. The two sources provide a value for each of the property for the object. It has to
also be noted that every source need not always provide a value for the object.
6.2.5.2 Methods
The central theme of truth discovery has been to discover truth from minorities. The three common
approaches to all the methods in the literature can be divided into two main categories namely (i)
probabilistic frameworks and (ii) iterative methods [82]. The first method is based on probabilistic
graphical models (PGM) that uses a likelihood function of the general form given by Equation 6.1.















The iterative methods are straightforward where the source weights and the truth computation are
alternatively optimized until convergence. While optimizing one of them, the other parameter
is considered to be fixed. The truth is computed as a weighted inference like voting. Equation
6.2 represents a general form of the objective function used to estimate source weights and truth
alternatively until convergence. f (vso,v
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Some of the methods that address various aspect(s) of truth discovery are already considered as
benchmark methods in this area. The algorithms might be greatly diverse and hence comparing
them on a single scale is not possible. We summarize here, some of the widely used methods. 2-
estimates is a method that is based on the single truth assumption using complimentary voting and
an extended version of the same called 3-estimates additionally models the difficulty of obtaining
the truth of an object [50]. LTM [132] is a method based on PGM which detects multiple truths
while TruthFinder is a Bayesian model that iteratively estimates source weights and truths [145].
6.3 Applications of Truth Discovery
People post reviews about medicines, physicians, books, restaurants and various other topics.
These reviews however lack quality if we were to look at just one online portal. practically, the
audience read multiple platforms to form an opinion on what might be true. In applications such as
healthcare, it is often essential to know the truth since a wrong piece of information can mislead the
audience. Discovering the truth helps both patients, doctors as well as the pharmaceutical industry
[94]. Crowd sensing is a field which can be a high motivating application for truth discovery. With
the popularity of social media, a lot of information is updated on social platforms. Unfortunately
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most of them are outdated and act as mere noise. For example, when a natural disaster hits a partic-
ular geographical location, people post about the supplies needed and this information is copied by
several sources. Unfortunately such data are not updated and keep floating around even much later.
Learning from such highly noisy data can be very challenging and a few studies have addressed it
[120][121]. Conflict also arises when different people accrue data from different platforms. There
can be inconsistencies in labelling between two people and given a time frame, different people
collect different sizes of data. In the end, truth discovery can be used to find the truth from a bunch
of incomplete data [125].
6.4 Conclusion
In spite the numerous frameworks that have been put forth by various groups, there are still huge
gaps that need to be addressed. Truth discovery in itself poses a lot of challenges like the ones we
summarized here. Hence there is tremendous scope for improvement in terms of data, methodol-
ogy and applications that might have specific challenges to name a few. All the work until now
have addressed only a couple of aspects and it is desirable to build a framework that unifies as
many factors as possible. Some applications cheminformatics have very specific challenges such
as dealing with conflicting data within a single source. These conflicts are not time based where
we could eliminate records based on their time stamp. They are results of physical experiments
and due to external conditions or some errors, the end values differ widely. Although these records
are often discarded, it is desirable to estimate the truth given that these experiments come at a cost
and time. Extracting useful information from them would prove to be valuable.
Truth discovery has also been explored within a very limited scope in terms of translating it
to a learning problem. Although it might be complicated, a framework on those lines would open
new avenues in this field. In the next chapter, we propose a framework for truth discovery that
loosely adapts from multi-view multi-task learning frameworks.
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Chapter 7
A Semi-supervised Approach for Truth
Discovery
7.1 Introduction
We are currently in the era of data explosion where there is so much data all around but we are
not sure if they are all true. In many situations when we seek to look for a particular information,
we are bombarded with facts from multiple sources. For example, if we search for the population
of Kansas, we are able to get information from Wikipedia, the census bureau and from election
campaigns. In most cases, all the three sources do not claim the same value for the question in
place. This conflicting information serves as a motivation for truth discovery which aims at finding
the truth about an object from heterogeneous sources.
An intuitive way of resolving such conflicts is to find the mean across the sources if the data is
numerical or get a majority voting on them if the data is categorical. This straightforward method
does not work very well when the number of false data is more. This method indirectly biases the
truth towards the "majority is right" idea. In the real world, many sources copy from each other.
During this process, if the false information is duplicated, our voting/averaging method would fail.
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Hence it is utmost important to asses the quality of each source in terms of their reliability.
Several features of truth discovery have been explored with more research being done con-
stantly to improve the estimation of source reliability. Here we present a semi-supervised setting
to truth discovery where we assume that a small set of ground truths is known. The proposed work
incorporates multiple data types like the CRH framework proposed by Li et al., [82]. We funda-
mentally model the problem to comprise of two different tasks (entries with known and unknwon
ground truths) that learn the source reliabilities from each other. Our experimental study shows
that the proposed method achieves better accuracy than similar methods.
7.2 Related Work
The central theme of truth discovery has been to estimate the reliability of sources that ultimately
help in finding the truth as closely as possible. The setting and constraints under which these
reliabilities are estimated are diverse and we summarize a few methods that closely relate to our
problem setting. We divide the literature based on the availability of ground truth namely (i) un-
supervised and (ii) semi-supervised approaches. In a setting where no ground truth is known, Li
et al [82] proposed a unified framework called CRH that estimates the truth as a weighted sum of
the sources by learning the weights and truths alternately without any prior knowledge on neither
of them. The CRH framework also has the capacity to handle numeric as well as categorical data
which none of the previous methods had. Other benchmark methods such as 2-Estimates and 3-
Estimates brought in a direction to systematically extract truth in the presence of conflict. These
methods however dealt only with categorical data. The 2-Estimates worked on an assumption that
there can be only one truth for each entry.
A semi-supervised truth discovery framework proposed by Yin et al., demonstrated the effec-
tiveness of having ground truth, even if small in number went a long way in more accurately finding
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the truth from conflicting sources [133]. They closely adapt the semi-supervised graph learning
approach that tries to predict the labeled samples in addition to the structure of the graph. All of
the approaches focus only on one type of data except CRH which contributes mainly in handling
heterogeneous data which has shown that exploiting both types of data is more effective in studying
the reliability of the sources than estimating source reliability using just one type of data.
7.3 Notations
In this paper, we used bold uppercase letters to represent a matrix (e.g. X) and bold lowercase
letters to represent a vector (e.g. x). Greek letters are used to represent Langrange multipliers
(e.g. λ1), simple lower and uppercase letters ar eused to represent scalars (e.g. x,X). We use the
subscript s to denote a source. For example, if we have S sources, Xs represents data X from source
s where s ∈ S. All the vectors are column vectors unless specified.
7.4 Methodology
In this section, we describe the framework of our proposed methods that aim at learning the truths
from heterogeneous sources on multiple reported facts.
7.4.1 Problem Setting
We formally define the problem setting as follows. Every observation is called an object and
each object can have one or more properties. For example, "John" is an object and "height" and
"weight" are the properties of the object. The value for each property could be provided by one or
more sources. The value of an object reported by different sources need not necessarily agree with
each other which is the motivation for truth discovery. We represent the data from source ‘s’ as
Xs where s ∈ S. ‘xsi j’ denotes the jth property of object ‘i’ from source ‘s’. For both our methods
proposed, we assume that a small set of truths are known and the truths are known at random. So
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we might know the true value for the jth property of an ith object from source s. We do not assume
that we know all the properties of an object.
Figure 7.1: The figure represents our problem setting where the known ground truths are shaded
in yellow. The rows represent the objects and the columns represent the properties.
7.4.2 Learning with Strong and Weak Truths
The first method we propose is called ’Truth Discovery using Strong and Weak Truths’ - LSWT. We
draw the inspiration for this method from the concept of multi-task learning in machine learning.
The hypothesis is that learning closely related tasks together improves the overall performances of
all the tasks. We adopt a similar idea of considering the objects with known ground truths and the
objects with unknown ground truths as two different but related tasks. Instead of combining the
two types of objects together and weighting the sources, we weight each "task" separately but add
a constraint that the weights of the two tasks should be similar.
We first partition the data into objects with known ground truths X and objects without any
known ground truth U . We use two different parameters β and α to weight X and U respectively.
The corresponding truths of the two tasks are represented by X∗ and U∗. While X∗ are the ground





















































In the above equation, L(·) defines the loss function and is based on the data type of the object’s



















































7.4.3 Computing Source Weights
The optimization for this framework is performed by alternately updating the source weights and
truths by solving Equation 7.2. With known ground truths X∗, we solve for β by taking partial
























By substituting Equation 7.4 into the constraint ∑
s′










































We can similarly obtain an expression for αs by differentiating Equation 7.2 with respect to αs


























As a first step to computing the truth, we first define L(x∗nm,x
s
nm) for each type of data. For contin-
uous data, the loss function is the normalized square loss of the ground truth and the fact claimed







For categorical data, we use a binary vector to represent all the possible values for a particular
property of an object. We encode the presence of a value with a 1 and 0 otherwise. For example,
if the jth property of the ith object has 5 possible values across s sources, we represent the vector









nm− Isnm)T (I∗nm− Isnm) (7.10)
Similar to computing the source weights, we solve for truth update of each task separately. We





































We use the expressions from Equations 7.6, 7.7, 7.12 and 7.13 to update the source weights
and truths of the two tasks until convergence.
7.4.5 Updating Truth
Updating numeric data is pretty straightforward. We update categorical data by the following
manner. If we have two sources and the source weights are 0.3 and 0.7 respectively, and if the
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binary vectors are (0,1) and (1,0) then the truth for the property would be the value with a higher
probability. In this case,
(0,1)∗0.32 +(1,0)∗0.72
0.32 +0.72
= (0.845,0.155). So the truth is updated by
the first value with a probability of 0.845.
Algorithm 3 Learning with Strong and Weak Truths
1: Input: X∗, U∗, {Xs}Ss=1, {Us}
S
s=1, γ , Nit , ε
2: Output: X∗, U∗
3: αs0 =
1
S , βs0 =
1
S
4: for iter = 1 to Nit do
5: for s = 1 to S do
6: Compute βs as given by Equation 7.6
7: Compute αs as given by Equation 7.7
8: Compute X∗ as given by Equation 7.12
9: Compute U∗ as given by Equation 7.12
10: end for
11: ‖βs−βs0‖< ε & ‖αs−αs0‖< ε
12: break
13: βs0 := βs for each s ∈ [1 : S]
14: αs0 := αs for each s ∈ [1 : S]
15: end for
16: Return X∗ and U∗
7.4.6 Choice of Source Weight Computation
The regularization we have enforced in our method constraints the sum of the weights to be equal
to 1. This constraint does not allow dissimilar sources to have a wide variation in source weights
especially if the number of sources are in the thousands. Li et al, in their CRH framework propose a
regularization that maps the source weights in the 0-1 range to a 0-inf range. This allows to magnify
the differences between the sources. We briefly present that regularization for our framework that
involves the two sets of data that are related to each other.
Parameters ts and rs are introduced where ts = exp(−βs) and rs = exp(−αs). To accommodate














































To solve for the source weights we differentiate Equation 7.14 with respect to tk and set the



























































































7.5.1 Real-world Data Sets
To demonstrate the effectiveness of the proposed methods, we consider two sets of data (i) synthetic
and (ii) real-world data. The details of each data set is explained below.
7.5.1.1 Simulated Data Set
We utilized two data sets from the UCI repository namely the Adult Data Set and the Bank Data
Set. Both these data sets contain numeric as well as categorical data set. Although the data sets
have a label and are typically used for classification, we ignore the labels and use just the data.
The Adult data has 32561 objects and 14 properties. The Bank data has 45211 objects and 17
attributes. The former had missing values whereas the latter did not. The actual data was regarded
as the ground truth and we generated four different versions of the data with conflict with the
ground truth. These four versions are considered as four different sources.
We artificially alter the truth for each source in such a way that the first source has very few
altered ground truths and the second has more conflicts than the first and so on. This would mean
that the algorithm would learn a higher weight for source 1 compared to the other three sources.
Source 4 would have the least weight with sources 2 and 3 having weights in between 1 and 4.
For continuous data we add Gaussian noise and for categorical data, we randomly alter the truth to
create a conflict. The characteristics of both these data sets are tabulated in Table 7.1.
7.5.1.2 Weather Data Set
We got the weather dataset from Qi et al., [] who collected and processed this data for their CRH
framework. The data was collected from three websites namely Wunderground, World Weather
Online and HAM weather. The three websites were crawled for three days to obtain the forecasts
for a few US cities in terms of their high temperature, low temperature and weather condition.
Since the three websites were crawled for three days, the resulting data was considered as nine
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different sources. This dataset is a good representation for heterogeneous data since it has both
numerical (two temperatures) and categorical data (weather condition). Similarly the ground truth
for about 20 US cities was obtained from true weather for over a period of 1 month. The ground
truth was obtained only for a subset of the samples.
Table 7.1: Statistics of the three data sets
Weather Data Adult Data Bank Data
# Observations 16038 3646832 5787008
# Entries 2100 455854 723376
# Ground Truth 1740 455854 72336
The table information is as follow: The number of objects in Adult data is 32561 with 14
properties each which makes the number of entries per source equal to 455854. We artificially
create 4 views thereby making the total number of observations to be 130244. The ground truth is
known for all the observations in the case of Adult and Bank data sets.
7.5.2 Comparison with Other Methods
We compared the proposed algorithm with the following relevant methods that are similar and
comparable.
• The baseline voting/average method.
• The CRH framework proposed by Qi et al., where no ground truth is used. The method is
initialized with the average/majority voting for numerical/categorical data type respectively.
• Use the CRH framework with a few ground truth labels. In this case, some of the data would
have the ground truth as the initializing point while the rest of them would be initialized with
the average or voting rule. We call this CRH-SS.
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Some other benchmark methods such as 2-Estiamtes, 3-Estimates and TruthFinder have not
been compared with since all of them utilize only one data type and the CRH framework has
already shown to perform better than these methods.
7.5.3 Performance Measure
For all the methods, the errors on the categorical data and numeric data are estimated based on
two different strategies. We use Error Rate for categorical data which is the percentage of output
different from the ground truth. Similarly for the continuous data, we calculate the distance of the
output from the ground truth. We further normalize the error by the variance since each property
might have a different range. We then calculate the mean of this normalized error called the Mean
Normalized Absolute Distance.
7.5.4 Choosing the Ground Truth
This study explores truth discovery in a semi-supervised setting. The CRH framework does not
need any ground truth. The CRH-SS and LSWT use ground truth on a small subset of entries. To
do this, we randomly select these ground truths to replace the initialized entries. For the set of
experiments where we show the impact of ground truth on the accuracy, we vary the number of
truths from 10 to 1000. For lower number of ground truths, we tried to make sure we had both
numeric and categorical data represented.
7.6 Results
We conduct two sets of experiments. The first one was to study the advantage of having a small set
of known ground truths. We compared the performance of the proposed LSWT method to CRH,
CRH-SS and Voting/Mean methods. The second experiment shows the effect of the number of
ground truths on the performance. We did these experiments for all the three data sets.
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Table 7.2: The performance of the methods with 500 known ground truths
Method
Weather Adult Bank
Error Rate MNAD Error Rate MNAD Error Rate MNAD
CRH 0.3983 4.6849 0.0000 0.1014 0.0000 0.1027
CRH-SS 0.3983 4.6849 0.0000 0.1014 0.0000 0.1027
LSWT 0.3660 4.2017 0.0000 0.0693 0.0000 0.0785
Voting 0.4845 NA 0.2013 NA 0.2941 NA
Mean NA 4.7853 NA 0.4632 NA 0.4891
Table 7.2 lists the errors on the three data sets. For this experiment, we chose the number of
known ground truths to be 500. In all of the experiments CRH does not use any ground truths.
Instead, CRH initializes the truth for its entries with the major voting for categorical entries and
with the mean value for its numeric entries. CRH-SS follows the same procedure but we replace
some of the entries with the ground truth. For the LSWT method, we group the entries with ground
truth as one task and the bigger number of entries with no ground truth as another task whose truths
are initialized with the voting/mean method.
For each data, we represent the performance with two different parameters namely the error
rate for categorical data and MNAD for the numeric data. First, we take the weather data set that
represents a real world data. As a quick observation, we see that the error rate and MNAD values
for LSWT is the least compared to the other three methods. We see that on the categorical data,
the voting approach performs the worst. This is due to the fact that if majority of the sources had
a false value, voting would be in favour of it. Given that the sources may copy from each other,
a wrong fact that is copied will bias the result to favour it. The same reason holds good for the
MNAD values since the mean just takes a simple average of continuous data and the squared error
from the ground truth might be huge. As a second observation, the CRH and CRH-SS perform the
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Table 7.3: Effect of known ground truths on error rates for the weather data set
Method
Number of known truths
10 25 50 100 200 500 1000
CRH 0.3983 0.3983 0.3983 0.3983 0.3983 0.3983 0.3983
CRH+SS 0.3983 0.3983 0.3983 0.3983 0.3983 0.3983 0.3983
LSWT 0.3983 0.3948 0.3879 0.3862 0.3759 0.3660 0.3641
Voting 0.4845 0.4845 0.4845 0.4845 0.4845 0.4845 0.4845
same way irrespective of how the truth for the entries are initialized. This is because, for a convex
formulation, a random starting point would still ensure convergence to the optimum solution.
As for our proposed method, we learn two different weights for the set of entries with ground
truth and without ground truth. We enforce that the two weights be similar. So the weights esti-
mated using the ground truths act as a blue print for the weights that are estimated on the entries
without ground truth.
We see similar results for the Adult and Bank data sets where eight different versions of the
original data set were simulated to reflect eight sources with conflict. We can see that almost all
the methods accurately find the truth for the categorical data. This might be due to the fact that,
categorical data were just randomly flipped. The continuous data that had Gaussian noise added
was more prone to errors as shown in the results.
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Table 7.4: Effect of known ground truths on MNAD values for the weather data set
Method
Number of known truths
10 25 50 100 200 500 1000
CRH 4.6849 4.6849 4.6849 4.6849 4.6849 4.6849 4.6849
CRH+SS 4.6849 4.6849 4.6849 4.6849 4.6849 4.6849 4.6849
LSWT 4.5970 4.5233 4.5157 4.4821 4.3972 4.3948 4.2017
Mean 4.7853 4.7853 4.7853 4.7853 4.7853 4.7853 4.7853
Table 7.5: Effect of known ground truths on error rate and MNAD for Adult and Bank data sets
Known Truths
Adult Bank
Error Rate MNAD Error Rate MNAD
100 0.0000 0.0700 0.0000 0.0796
500 0.0000 0.0693 0.0000 0.0785
1000 0.0000 0.0524 0.0000 0.0692
2000 0.0000 0.04850 0.0000 0.0598
The second set of experiments involve varying the number of ground truths to study its effect
on the error. From Tables 7.3 and 7.4 we can notice that as the number of ground truth entries
is increased, the error rate and MNAD values decrease for LSWT. When we have as few as 10
known truths, CRH, CRH-SS and LSWT perform similarly. But as the number of known truths is
increased, the error rate and MNAD values reduce for LSWT but doesn’t have any impact on CRH
and CRH-SS due to the reasons discussed previously.
Table 7.5 shows the results for Adult and Bank data sets when the number of ground truths is
increased. Since CRH and the Voting/averaging method do not depend on the number of ground
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truths, we do not report their scores. CRH-SS on the other hand behaves like CRH for the reasons
mentioned previously. We report the scores for all teh methods in table 7.2. In Table 7.5, we report
the error for just LSWT. Typical to the weather data set, the MNAD values on the simulated data
decrease as the number of ground truths increases. For the simulated data, we got an error rate of
0.0000 on for all the three methods - CRH, CRH-SS and LSWT. This might be due to the fact that
categorical data were not altered too much while simulating the data.
7.7 Conclusion
In the field of truth finding, estimation of source reliability is the principal idea that results in
efficient discovery of the truths. Among the many challenges that these problems pose the main
hurdle has been to estimate parameters of a source by combining different data types. In this
study, we propose a truth discovery framework that borrows inspiration from multi-task learning.
We hypothesize that in a semi-supervised setting, we define entries with known ground truths and
entries with unknown ground truths as two different but closely related tasks. We use two sets
of parameters to estimate the source reliability and constraint the parameters to be similar. With
experiments on both simulated and real-world data, we show that the proposed method performs
better than other similar methods in comparison. We hope to further improve this method by
incorporating a way to estimate multiple truths for each entry if any.
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Chapter 8
Conclusion and Future Work
This dissertation has explored the scope of semi-supervised approaches for two main applications.
We first conducted a detailed preliminary study of using multi-view learning in a semi-supervised
setting along with multi-task learning for predicting associations between drugs and diseases. This
empirical study opens up new avenues for exploring such algorithms since the use of unlabeled
samples is desirable in computational chemistry due to the limited availability of labeled samples
and a large number of unlabeled samples.
The first method we explained the weighted multi-view learning framework that weights each
feature space so that the final prediction is not the simple average of the views but a weighted
average of the views. The key feature of this method is that the weights are estimated without
any prior knowledge on the views. The belief is that there might be some feature spaces that have
better predictive power than the others and estimating them via view weights is more beneficial.
We then extend the weighted multi-view learning to multi-task with weighted multi-view learn-
ing since learning related tasks has shown to improve the overall performance of all the tasks than
learning them separately. Previous studies have shown that learning related protein targets or dis-
eases has been beneficial in the learning process. For both of the methods , we evaluated our
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algorithms on drug-disease and chemical-target data respectively.
We changed gears in the last chapter to apply semi-supervised learning to truth discovery. As
the name suggests, the objective of truth discovery is to mine data from heterogeneous sources
that present different facts about a piece of information and find the one that is closest to the ac-
tual truth. This problem of truth discovery has been mainly approached from the view point that,
estimating the reliability of a source would give an idea about the facts it presents. On the other
hand, estimating the source reliability depends on the facts it presents. This challenge of having
to learn source reliability along with the truths has led to the proliferation of many methods that
treat the many facets of truth discovery. One aspect of estimating the trustworthiness of sources
is to be able to leverage multiple data types in the source. Studies have shown that using all the
data types together in estimation is more accurate than estimating each of the data type separately.
The method we designed handles this in a semi-supervised setting. A lot of methods assume that
no ground truth is available but on the other hand, we suggest that a small number of ground truth
goes a long way in estimating the source reliabilities.
We borrowed the concept of multi-task learning from machine learning to show that the facts
without ground truth and the facts with ground truth could be considered as two tasks that are
very closely related. Our experiments with real world and simulated data showed that our prob-
lem setting led to more accurate finding of the truth than similar methods that were pitted against it.
Our future work would be in two different direction. The first is to incorporate a way to allow
each object to have multiple truths. We need to explore the possibility that each object and its prop-
erty can have one or more truths and the number of truths need not be the same across all objects
and properties. The second direction is to apply the concept of truth discovery to cheminformatics.
There are many public databases that have large data influx everyday. For example, experiment re-
sults of drug activity with proteins in terms of their IC50 value is added to the database. But due to
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variations in experiments, the results are not consistent. But a very challenging aspect of such data
is that, there are facts about the same object that are conflicting within the same database. Apart
from conflicts between sources, we have conflicts within the source too. Modelling this aspect of
such databases will substantially increase the number of useful data points that could be extracted
from such sources.
The application of truth discovery to the field of computational chemistry and bioinformatics is
largely unexplored. A large part solving this problem is also due to the fact that these applications
do not follow an agreed upon nomenclature that makes it harder to study them. But addressing this
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